Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
2016 ANNUAL REPORT From Our Leadership OUR MISSION: SAVE MORE LIVES We fuel the discovery and development of powerful immunotherapies for all types of cancer. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing the immune system’s power to conquer all cancers. We fund the most innovative research of young scientists, invest in clinical studies of promising new treatments, and provide patients and caregivers with information on the latest advances in cancer immunotherapy. With more than 60 years of experience funding research on the immune system and cancer, CRI is leading the way and ushering in a new era when patients, with all types of cancer, can be treated and potentially cured with immunotherapy. 1 From Our Leadership 2 Postdoctoral Fellows 4 Translational Research 6 Clinical Accelerator 8 Drug Development 10 Scientific Dialogue 12 Awareness & Education 14 Awards & Honors 16 Fiscal Year 2016 Grants & Awards 30 Fundraising 32 Donors 46 Financial Highlights 48 Governance & Guidance IN 2016, CRI SUPPORTED LABORATORY, TRANSLATIONAL, AND CLINICAL RESEARCH IN 13 COUNTRIES, INCLUDING 20 U.S. STATES. J ust five years ago, when talking about outcomes of patients treated for late-stage cancers, “cure” wasn’t a word our scientists were likely to use. Today, the outlook is significantly better, with cancer immunotherapy now offering patients a real chance—not only at surviving longer, but also at living better without the debilitating side effects often seen with conventional cancer treatments. At last, we can say that cures for cancer are within reach. This didn’t happen overnight. It has taken a long view of progress and decades of research to build a foundation for the new therapies available to patients today. Lifesaving drugs like the FDA-approved immunotherapies Yervoy®, Opdivo®, Keytruda®, Imlygic®, and others are built upon fundamental knowledge of the immune system, its components, and how they function. This knowledge was hard won by a global community of immunologists and tumor immunologists, many of whom have relied on funding from the Cancer Research Institute to carry out their important work. In fiscal year 2016 (July 1, 2015, to June 30, 2016), we continued to push the limits of human knowledge and open the way for new and more effective immunotherapies by awarding over $23.6 million to support highly promising laboratory, translational, and clinical research around the world. We also recognize the need to help patients and their caregivers navigate what can be an overwhelming introduction to this new treatment approach. In 2016, we invested in educational programming to provide them trusted information and connect them to immunotherapy clinical trials. And as part of our Cancer Immunotherapy Month awareness campaign in June, we introduced more than 3.8 million people worldwide to the exciting progress being made today thanks to immunotherapy breakthroughs. We are proud that we are able to make these important contributions to the global cancer research and patient communities while also maintaining our high ratings with charity watchdogs, including four out of four stars from Charity Navigator and membership within the Better Business Bureau’s Wise Giving Alliance, among others. None of this lifesaving work would be possible without the generous support of our donors like you, on whom we rely. We extend our heartfelt thanks on behalf of the thousands of CRI-funded scientists and the millions of cancer patients worldwide who may benefit from your support. PAUL C. SHIVERICK Co-Chairman of the Board ANDREW K. TSAI Co-Chairman of the Board JAMES P. ALLISON, PH.D. Director, Scientific Advisory Council JILL O’DONNELL-TORMEY, PH.D. CEO and Director of Scientific Affairs 58 Ways to Give CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 1 POSTDOCTORAL FELLOWS 29 NEW GRANTS $5.1 MILLION AWARDED IMPACT Powering Innovation The CRI Irvington Postdoctoral Fellowship Program provides training and financial support to young scientists working in the laboratories of leading cancer immunologists around the world. Fellowships provide up to $175,500 over three years. O ur postdoctoral fellows are the best and the brightest, bringing new energy to tackle the most pressing areas of research today. Their investigations deepen our knowledge of the immune system and lay the foundation for new immunotherapies for all types of cancer. In the past year: Leticia Corrales, Ph.D., of the University of Chicago, in Chicago, IL, engineered a small molecule of PD-1 and demonstrated its effectiveness in treating both small and large colorectal cancer tumors. Rony Dahan, Ph.D., of The Rockefeller University, in New York, NY, demonstrated how the tail region of checkpoint inhibitor antibodies can affect immunotherapy responses, providing key insights to support the development of next-generation checkpoint inhibitors. P.C. Dave P. Dingal, Ph.D., of Stanford University School of Medicine, in Stanford, CA, created a system that allows researchers to manipulate the activity of genes to better characterize and understand the immune system’s dynamics. Bengt Martin Gustavsson, Ph.D., of the University of California, San Diego, in San Diego, CA, developed new ways to design and analyze the binding affinity of a key immune molecule, called a chemokine, to enable more effective drug design. Jiazhi Hu, Ph.D., of the Boston Children’s Hospital, in Boston, MA, discovered how enzymes called RAGs can cause improper DNA rearrangements that have been implicated in B cell lymphoma, a deadly type of blood cancer. Helene M. Salmon, Ph.D., of the Icahn School of Medicine at Mount Sinai, in New York, NY, revealed how dendritic cells coordinate anti-melanoma responses, and developed an approach to enhance their anti-cancer activity in combination with checkpoint inhibitors. CRI is at the forefront of supporting innovative and highly promising research. As a postdoctoral fellow, I relied on CRI’s funding of my basic research, considered at the time by some as lacking cancer relevance. Yet, it turned out that it’s now one of the main focuses in cancer therapy development. RONY DAHAN, BENGT MARTIN GUSTAVSSON, P.C. DAVE P. DINGAL, AND MARGARET K. CALLAHAN Estela P. Jacinto, Ph.D. Associate Professor, Rutgers University CRI Irvington Postdoctoral Fellow, 1999-2002 FDA Approval M argaret K. Callahan, M.D., Ph.D., recently the Lloyd J. Old Memorial Fellow at Memorial Sloan Kettering Cancer Center in New York, NY, demonstrated in a phase III clinical trial for metastatic melanoma that combining the immunotherapies ipilimumab (Yervoy®) and nivolumab (Opdivo®) resulted in significantly longer progression-free survival than ipilimumab alone. In fiscal year 2016, the combination received FDA approval as a first-line treatment for melanoma. For a complete list of all 102 postdoctoral fellows active in FY2016, go to page 18 CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 3 TRANSLATIONAL RESEARCH 12 NEW GRANTS $2.4 Bridging Basic and Clinical Science The Clinic and Laboratory Integration Program (CLIP) supports scientists conducting translational research aimed at improving the effectiveness of immunotherapies. CLIP grants provide up to $200,000 over two years. R ecent clinical outcomes from immunotherapy trials have generated new scientific questions and high demand for research funding. CRI established CLIP to facilitate better dialogue between the laboratory and clinic. By channeling support into this “translational” area, CRI supports an iterative research loop that can lead to new and more effective immunotherapies. It’s difficult to secure funding for applied research projects like ours, and this unique grant allows us to pursue our efforts to improve the effectiveness of cancer immunotherapy. MILLION AWARDED Michael S. Goldberg, Ph.D. Assistant Professor of Cancer Immunology & Virology, Dana-Farber Cancer Institute CLIP Investigator, 2014-2016 IMPACT Power of Biomarkers H aidong Dong, M.D., Ph.D., a 2015-2017 CLIP investigator and associate professor of immunology at the Mayo Clinic in Rochester, MN, discovered that the Bim biomarker on T cells can predict how well patients might potentially respond to Seeking Out Immunosuppression in Ovarian Cancer Novel Target for Cancer Immunotherapy Beyond PD-1: In Search of a New Checkpoint Inhibitor Juan R. Cubillos-Ruiz, Ph.D. Assistant Professor of Microbiology and Immunology, Weill Cornell Medicine, New York, NY Amanda Lund, Ph.D. Assistant Professor of Cell & Developmental Biology; Molecular Microbiology & Immunology; and Dermatology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR Mark J. Smyth, Ph.D., FAHMS Senior Scientist and Immunology Coordinator, QIMR Berghofer Medical Research Institute, Brisbane, Australia While immune cells can slow and even halt ovarian cancer progression, immunosuppressive factors in the tumor environment can reduce their potency. Cubillos-Ruiz is investigating a newly recognized fatty acid, or lipid, that enables ovarian tumors to evade immune attack. He will study whether blocking the lipid’s receptor can enhance anti-tumor immune responses. Promising results could lead to therapeutic drug combinations that improve survival in ovarian cancer patients. Lund is working to improve our understanding of how lymphtransporting vessels affect our immune system’s ability to carry out anti-tumor immune responses against melanoma. Abnormal lymphatic growth is associated with cancer, and Lund hypothesizes that tumors may be “hijacking” these vessels to escape the immune system. Lund’s work may enhance immunotherapy approaches that target these vessels and improve survival in melanoma patients. immunotherapy, and provides a way to observe ongoing anticancer immune responses. If validated, this biomarker will help doctors to monitor an immunotherapy’s effectiveness in patients. Smyth is exploring a strategy that targets CD96, a receptor that can prevent immune cells like natural killer (NK) cells from eliminating cancer. He aims to determine whether blocking CD96 with an antibody, given alone and in combination with other treatments, can improve anti-tumor immunity. Smyth’s findings may lead to strategies to reduce tumor metastases and treat patients successfully. For a complete list of all CLIP investigators active in FY2016, go to page 22 CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 5 CLINICAL ACCELERATOR 2 NEW TRIALS 4 EXPANDED TRIALS A New Clinical Discovery Model The Anna-Maria Kellen Clinical Accelerator is CRI’s venture philanthropy program designed to help spur the creation of next-generation combination cancer immunotherapies through partnerships with academia and industry. C RI’s clinical program fosters collaboration across top academic research groups, biopharma companies, and nonprofit partners to design, conduct, manage, and fund scientifically-driven clinical trials with high potential for success. These trials make available to patients new and promising treatment combinations that they otherwise could not access. Prioritized studies are launched with a comprehensive set of nonprofit resources and a unique IP model that facilitates access to top drugs from different companies. Clinical Accelerator currently has more than 15 significant industry and nonprofit partners. The model is powered by a nonprofit venture capital fund, which enables it to achieve significant leverage via co-investments and is structured to become self-sustaining over time via returns on investment back to the charity as supported drugs demonstrate their effectiveness. The backbone of the program, the CVC Clinical Trials Network, is powered by more than 80 clinician scientists around the world and is managed jointly by CRI and its partner, Ludwig Cancer Research. It’s a win-win-win model: cancer patients gain access to promising new treatment options; scientists gain extraordinary clinical research and publication opportunities; and company partners gain valuable investment of nonprofit resources and expertise into their drugs. $15.6 David A. Reardon, M.D. Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute CVC Clinical Trials Network Member, 2012-present MILLION AWARDED IMPACT CRI’s Clinical Accelerator allows me to provide cutting-edge immunotherapy combinations to patients with glioblastoma, a type of brain cancer that is difficult to treat and which may be a promising target for immunotherapy. Hope for Cancer Patients T o date, Clinical Accelerator investments have supported 10 phase I and II cancer immunotherapy clinical trials. These trials are bringing novel immunotherapy combinations into the clinic and will ultimately treat over 800 patients spanning 20 types of cancer, including very hard-to-treat cancers like glioblastoma, a type of brain cancer, triple-negative breast cancer, and colorectal cancer. For a complete list of all active CRI-funded clinical trials, go to page 25 CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 7 DRUG DEVELOPMENT 23 PUBLICATIONS TO DATE 12 Harnessing Industry Expertise The Cancer Immunotherapy Consortium (CIC) is a think tank of industry leaders from the cancer immunotherapy field who seek solutions to challenges in late-stage drug development, with the goal of accelerating patient benefit. T he CIC was founded in 2002 as an international membership association of pharmaceutical and biotechnology companies and academic institutions with a common interest in immunotherapy research and development, with the ultimate goal of making cancer immunotherapies part of the standard-of-care in oncology. With the 2011 FDA approval of ipilimumab (Yervoy®), an immune checkpoint inhibitor drug, the first milestone toward this goal was achieved. Given the substantial increase in development activity and clinical success of other immunotherapy agents that followed, and in an effort to continue to provide maximum value to the rapidly evolving field, the direction of the CIC was re-set to become a “think tank” that would convene and tackle topics of importance to the continued development of cancer immunotherapies. The CIC now acts as a neutral platform whereby industry representatives work together to discuss important issues and collectively facilitate solutions to challenges in late-stage drug development, with the goal of accelerating patient benefit. Outcomes will be available to all stakeholders in the field through publishing of CIC proceedings. Current topics under review include application of immune-related Response Criteria (irRC) across clinical studies in multiple tumor types, and second-generation biomarkers. Through the CIC, companies with immunotherapies in development can work together toward the same goal, finding solutions that will help the entire industry and, ultimately, cancer patients. Daniel S. Chen, M.D., Ph.D. Vice President, Global Head of Cancer Immunotherapy Development, Genentech/Roche Co-Chairman, CIC Steering Committee INDUSTRY REPRESENTATIVES IMPACT Finding a Common Language I n 2016, CIC Steering Committee members identified important next steps toward the development of shared definitions of patient outcomes that can be used across different companysponsored drug trials when describing tumor progression within the context of immunotherapy treatment. The development of common methods for assessing and reporting patient outcomes may allow for improved trial design and generation of data that facilitates FDA review of new immunotherapies. To learn more about the Cancer Immunotherapy Consortium, visit cancerresearch.org/cic CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 9 SCIENTIFIC DIALOGUE 1,400+ PARTICIPANTS 375 POSTERS PRESENTED Translating Science Into Survival The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference is a scientific meeting devoted to exploring the latest research in cancer immunology and immunotherapy. It attracts clinicians, scientists, government regulators, drug developers, and patient groups. W ith the explosion of interest in cancer immunotherapy and the proliferation of scientific meetings in the field, the Cancer Research Institute, along with the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR), decided to join forces to sponsor the International Cancer Immunotherapy Conference devoted to exploring the latest research in cancer immunology and immunotherapy. The theme of the inaugural September 2015 meeting, held in New York City, was “Translating Science Into Survival,” and featured over 60 presentations from leaders in immunology and cancer immunotherapy. Emerging themes included new genetic targets for personalized immunotherapies, the relationship between the microbiome and cancer, and new targets for checkpoint blockade, chimeric antigen receptor (CAR) treatment, and vaccine therapy. There was also a snapshot of the regulatory landscape for cell and gene therapy, biomarkers and their function in patient selection, imaging and its role in targeting the anti-tumor response, and immunotherapy trial designs. The International Cancer Immunotherapy Conference brings together prominent and promising researchers in cancer immunology and immunotherapy from around the world for one of the most important meetings of its kind. Steven A. Rosenberg, M.D., Ph.D. Chief, Surgery Branch, Senior Investigator, and Head, Tumor Immunology Section, National Cancer Institute, NIH Keynote Speaker, Inaugural International Cancer Immunotherapy Conference IMPACT Convening a Global Audience T he September 2015 conference attracted more than 1,400 participants from 38 countries across Asia, Australia, Europe, North America, and South America. More than 375 scientists presented their research at the meeting’s poster sessions, and CRI postdoctoral fellows and other meeting participants took advantage of the many networking opportunities. Due to high demand, the organizers hosted a second conference in 2016 in New York City, and a third will take place in Mainz/Frankfurt, Germany in 2017. To learn more about the conference, visit cancerimmunotherapyconference.org CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 11 AWARENESS & EDUCATION Connecting Patients, Saving Lives CRI is committed to educating patients, caregivers, and broader public audiences on important developments in cancer immunotherapy research and treatment. C ancer immunotherapy is a fast-moving field, and keeping up can be challenging. We provide educational programs and awareness initiatives designed to reach people who are unaware of immunotherapy’s promise and connect them to resources and communities that can help them on their treatment journeys. Preferred Destination for Trusted Information More than 1 million website visitors per year rely on free information we provide on immunotherapy research and treatment for more than 20 different types of cancer. Immunotherapy Clinical Trial Finder This fully supported service, the only one of its kind devoted exclusively to cancer immunotherapy trials, has helped more than 4,500 people take the first step in exploring their immunotherapy options. 3.8 MILLION PEOPLE REACHED 500k VIEWS OF EDUCATIONAL PROGRAMMING IMPACT Cancer Immunotherapy Month This series of educational, social, and athletic events in June promotes awareness of cancer immunotherapy and raises funds to support lifesaving research. Our most recent June activities featured: • Immunotherapy Patient Stories: Inspiring videos of patients sharing their experiences with cancer immunotherapy • Cancer Immunotherapy and You: Free webinars for patients and caregivers featuring immunotherapy experts and interactive Q&A • Immunotherapy and Chemotherapy: What’s the Difference?: Animated video explaining how these treatments work as well as their potential benefits and possible side effects • Ask a Scientist: Short videos inviting immunotherapy experts to address the most frequently asked questions from patients • What Cancer Patients Should Know: Latest Immunotherapy News from ASCO 2016: An expert panel discussing new developments in cancer immunotherapy research and treatment from the world’s largest cancer conference Social Media and Offline Special Events • #WhiteOutCancer Day: This global social media event invited people to show their support for cancer immunotherapy research by wearing white and posting a “selfie” to Facebook, Twitter, and Instagram or by uploading a personalized message with a photo to our website at whiteoutcancer.com • Answer to Cancer Cycling Event: On June 25, 2016, more than 220 cyclists rode 100, 50, or 25 miles through historic West Point and the surrounding Lower Hudson Valley in New York during this inaugural fund- and awareness-raising event sponsored by BristolMyers Squibb • Corporate Events: Participating companies around the world engaged thousands of their employees in day-long awareness, education, and fundraising activities designed to highlight progress in cancer treatment and promote company commitment to social responsibility and employee health Thank you to all of our generous partners and supporters Abbvie; Agenus; Basin Holdings; Bristol-Myers Squibb Company; Brooklyn Brewery; Celldex Therapeutics, Inc.; Clayton, Dubilier & Rice, LLC; Debevoise & Plimpton LLP; Finish Line Physical Therapy; Genentech; Hincapie Sportswear; Holowesko Citadel; Horseneck Wines & Liquors; Hudson Valley Harvest; Inovio Pharmaceuticals; LabAnswer and its employees; Merck, known as MSD outside the U.S. and Canada; Mitsubishi UFJ Securities; Nestle Waters North America; NewLink Genetics; PPD; Regeneron Pharmaceuticals; Reynolds Cycling LLC; The Sweat Life; Tailwind Endurance; and USA Cycling The more people who enter trials, the more people who are educated, the more power we as patients have. Stephen E. colorectal cancer survivor Awareness O ur education and public awareness programming reached more than 3.8 million people last year, introducing them to cancer immunotherapy breakthroughs and patient stories of hope, and providing them with information that can help them or a loved one during a cancer diagnosis. Health care professionals such as oncology nurses and community oncologists also found our many resources helpful for their ongoing professional education. To learn more, visit cancerresearch.org/june CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 13 AWARDS & HONORS 155 SCIENTIFIC AND LAY INDIVIDUALS AND ORGANIZATIONS RECOGNIZED TO DATE Recognizing Excellence Each year, the Cancer Research Institute honors individuals and organizations that have made important contributions to the field of cancer immunotherapy. I’ve always thought immunotherapy had an enormous potential to create an ongoing engine of opposition to cancers. Bill Clinton 42nd President of the United States Keynote Speaker, CRI 39th Annual Awards Dinner The William B. Coley Award for Distinguished Research in Basic Immunology Alexander Y. Rudensky, Ph.D., Memorial Sloan Kettering Cancer Center, Howard Hughes Medical Institute, New York, NY, for his contributions to our understanding of regulatory T cells, which play an important role in restraining immune responses and inflammation The William B. Coley Award for Distinguished Research in Tumor Immunology Glenn Dranoff, M.D., Novartis Institutes for BioMedical Research, Cambridge, MA, for his many contributions to the development of cancer immunotherapies, including the design and testing of the therapeutic cancer vaccine GVAX The Frederick W. Alt Award for New Discoveries in Immunology Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY, for her pioneering work on dendritic cells, which are key antigen-presenting cells that play an important role in starting the immune response AACR-CRI Lloyd J. Old Award in Cancer Immunotherapy Ronald Levy, M.D., Stanford University School of Medicine, Stanford, CA, for his work on developing rituximab (Rituxan®), the first monoclonal antibody to be approved by the FDA, in 1997 The Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research Kenneth C. Frazier, Chairman and CEO, Merck & Co., for advancing immuno-oncology research and drug development Lauren S. Veronis, Trustee, Cancer Research Institute, and Former President, Irvington Institute for Immunological Research, for her many years of devotion to advancing immunological research through her leadership and fundraising efforts THE METROPOLITAN CLUB IN NEW YORK, NY; KENNETH C. FRAZIER AND CRI TRUSTEE PAUL C. SHIVERICK; ALEXANDER Y. RUDENSKY AND CRI SCIENTIFIC ADVISOR PHILIP D. GREENBERG; AND LAUREN S. VERONIS AND CRI CEO AND DIRECTOR OF SCIENTIFIC AFFAIRS JILL O’DONNELL-TORMEY To view all CRI award recipients, visit cancerresearch.org/honorees CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 15 FISCAL YEAR 2016 GRANTS & AWARDS Funding the Best Science In fiscal year 2016 (July 1, 2015, to June 30, 2016), the Cancer Research Institute awarded more than $23.6 million for cancer immunology research and cancer immunotherapy clinical development. * Denotes grants newly awarded in fiscal year 2016. All others are active grants awarded in previous years. 22 STATES 13 COUNTRIES 83 INSTITUTIONS 20+ CANCERS UNDER STUDY CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 17 STUDENT TRAINING AND RESEARCH IN TUMOR IMMUNOLOGY (START) PROGRAM Two-year awards that attract bright young minds to rewarding careers as cancer immunologists by funding graduate studies in tumor immunology at top universities. Lomonosov Moscow State University, Moscow, Russia Sergei A. Nedospasov, Ph.D., D.Sc. Lloyd J. Old Advanced Training Program in Immunology and Oncoimmunology Heng Ru, Ph.D. Structural and biochemical studies of the antigen receptor gene recombination machinery Liman Zhang, Ph.D.* Structural studies of NAIP/NLRC4 inflammasomes in immunity and cancer Massachusetts General Hospital, Boston, MA Alexandria Huynh The role of PTEN in regulatory T cell stability and immune surveillance CRI IRVINGTON POSTDOCTORAL FELLOWSHIP PROGRAM Three-year awards that further the career development and advanced laboratory research of promising postdoctoral fellows working under the mentorship of world-class immunologists and tumor immunologists. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA Thomas Chia Ting Fung Role of innate lymphoid cellcontrolled intestinal barrier function in hepatocellular carcinoma Boston Children’s Hospital, Boston, MA Zhaoqing Ba, Ph.D.* Mechanisms that mediate intralocus and inter-locus regulation of V(D)J recombination at immunoglobulin light chain loci Samuel and Ruth Engelberg Fellow Livnat Jerby, Ph.D.* Integrating CRISPR with singlecell RNA-sequencing to map the underlying circuits of immune evasion mechanisms in melanoma The Hearst Foundations Fellow Bradley Wayne Blaser, M.D., Ph.D. Immunologic regulation of hematopoietic stem cell engraftment California Institute of Technology, Pasadena, CA Andrew I. Flyak, Ph.D.* The structural basis of hepatitis C virus neutralization by broadly neutralizing human antibodies University of California, Berkeley, Berkeley, CA Thornton William Thompson The role of oncogene-induced senescence in promoting antitumor immune responses F.M. Kirby Fellow PREDOCTORAL EMPHASIS PATHWAYS IN TUMOR IMMUNOLOGY Four-year awards to universities to support establishment and maintenance of tumor immunology training courses for graduate students. Liron David, Ph.D. Molecular elucidation of the CBM complex in NFκĸB activation by antigen receptors Jiazhi Hu, Ph.D. Mechanisms that target AID for antibody gene diversification and for oncogenic chromosomal translocations Robertson Foundation Fellow Johns Hopkins University School of Medicine, Baltimore, MD Director: Charles G. Drake, M.D., Ph.D. Cheng-Sheng Lee, Ph.D.* Elucidating the mechanism and the impact of RAG tracking University of Colorado, Denver, CO Directors: John Kappler, Ph.D., and Philippa Marrack, Ph.D. Immunology / Tumor Immunology Training Course Qi Qiao, Ph.D. Mechanistic elucidation of activation-induced deaminase in immunity and cancer Broad Institute of MIT and Harvard, Cambridge, MA Le Cong, Ph.D.* Dissection of cellular states and transcriptional networks regulating innate immunity during tumorigenesis Children’s Hospital of Philadelphia, Philadelphia, PA Nathan Roy, Ph.D.* Modulation of T cell trafficking by Crk adapter proteins Columbia University Medical Center, New York, NY Yenkel Grinberg-Bleyer, Ph.D. Testing the role of NFĸκB in tumor immunity through its effect on regulatory T cells Dana-Farber Cancer Institute, Boston, MA Adam N.R. Cartwright, Ph.D.* Systematic discovery of combination immunotherapy targets Emory University, Atlanta, GA William H. Hudson, Ph.D.* Deciphering the role of long non-coding RNAs in CD8+ T cell differentiation Harvard Medical School, Boston, MA Carmen Gerlach, Ph.D. Differentiation, function, and dynamic behavior of transitional memory cells: A novel subset of CD8+ memory T cells Alexandra M. Greer, Ph.D.* The role of ubiquilin-1 in B cell receptor-driven lymphoma proliferation Jason Hudak, Ph.D. Understanding microbial sensing in colorectal cancer using bioorthogonal chemistry Chaoran Li, Ph.D.* Differentiation and accumulation of adipose-tissue regulatory T cells: Important players in the immunological control of metabolism and obesityassociated cancer Kathleen A. McGuire, Ph.D. The role of the PD-1/PD-ligand pathway in anti-tumor immunity Kristen E. Pauken, Ph.D. Anti-PD-1 immunotherapy: Mechanisms and impact on sustainability of CD8+ T cell responses Robertson Foundation Fellow Harvard T.H. Chan School of Public Health, Boston, MA Lior Lobel, Ph.D.* Identifying novel effectors of the gut microbiota that modulate cancer cells killing by CD8+ T cells using functional metagenomics Simone Becattini, Ph.D.* Exploring colonization resistance against Listeria monocytogenes in cancer patients Icahn School of Medicine at Mount Sinai, New York, NY Helene M. Salmon, Ph.D. Contribution of the cutaneous myeloid network to melanoma response to therapy Robertson Foundation Fellow Pu Gao, Ph.D. Structural and functional studies of cytosolic DNA sensing pathway Robertson Foundation Fellow Institut Curie, Paris, France Yvonne K. Mburu, Ph.D. Mucosal-associated invariant T cells in anti-tumor therapy Lloyd J. Old Memorial Fellow La Jolla Institute for Allergy and Immunology, La Jolla, CA Chan-Wang J. Lio, Ph.D. Role of long non-coding RNAs in the development of T cell leukemia Christophe Pedros, Ph.D.* Control of regulatory T cell function by protein kinase C-beta (PKCη): A novel target for cancer immunotherapy Massachusetts Institute of Technology, Cambridge, MA Alexandra Boussommier, Ph.D. Characterizing the role of macrophages in breast cancer cell extravasation and recolonization in organ-specific 3D microfluidic models Jesse Green, Ph.D. Interactions of regulatory T cells with the tumor endothelium and effects on the tumor microenvironment Samuel and Ruth Engelberg Fellow Jing-Ping Hsin, Ph.D. The effects of cellular context on miR-155 mediated regulation of gene expression Young Philanthropists Council Fellow Wei Hu, Ph.D. Tissue repair function of regulatory T cells during infection and cancer progression Fella Tamzalit, Ph.D. The role of the centrosome in cytotoxic T cell function Lloyd J. Old Memorial Fellow Maria P. Frushicheva, Ph.D. ZAP-70 and Syk regulation in B cell chronic lymphocytic leukemia FELLA TAMZALIT, PH.D. Li Tang, Ph.D. T lymphocyte engineering with interleukin-2-silica nanocapsules for targeted cancer therapy Memorial Sloan Kettering Cancer Center, New York, NY Michael C. Abt, Ph.D. Innate immune regulation of C. difficile-driven inflammation CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 19 NYU Langone Medical Center, New York, NY Priya Darshinee A. Issuree, Ph.D. Roles of Runx3 in inflammatory T cells and colorectal cancer Hao Xu, Ph.D.* Identification of the RORγt ligands, protein complexes, and targeting signals involved in Th17 cellmediated homeostasis and pathogenesis WEI HU, PH.D. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Michael G. Constantinides, Ph.D. Role of the microbiome in lung cancer Vanessa K. Ridaura, Ph.D. Understanding the contributions of the skin microbiota to efficacy of melanoma immunotherapy Ivan Vujkovic-Cvijin, Ph.D.* Identifying novel microbiomebased immunotherapeutics for melanoma National Institute on Aging, Baltimore, MD Geoffrey Lovely, Ph.D.* Watching RAG recombinase assembly on the IgH locus and offtarget assembly in live pro-B cells National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, Bethesda, MD Claudia Ouyang, Ph.D. Non-apoptotic functions of the TNF-family receptor Fas: Mechanisms and implications for autoimmunity and tumor immunotherapy Mo Xu, Ph.D. Intestinal microbiota-induced Th17 responses in systemic inflammatory disease Margaret Dammann Eisner Fellow Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA Mohamed Abdel Hakeem, Ph.D.* Reprogramming of exhausted T lymphocytes following cure of chronic viral infection: Implications for immunotherapy The Rockefeller University, New York, NY Rony Dahan, Ph.D. Enhancing monoclonal antibodymediated immune responses within the tumor microenvironment Harald Hartweger, Ph.D.* The effect of replicative stresses on the genesis of chromosome translocations Shengdong Ke, Ph.D. RNA epigenetic HITS-CLIP: A new approach to understanding leukemia/lymphoma Yen-Chih Wang, Ph.D.* Chemical biology of microbiota protection against gastrointestinal cancer Stanford University School of Medicine, Stanford, CA Paola A. Betancur, Ph.D. In search of the gene regulatory circuitry responsible for the transcriptional upregulation of CD47, the “don’t eat me” signal in cancer cells P.C. Dave P. Dingal, Ph.D. Programmable cancer recognition using a chimeric system of Notch and CRISPR Julia Kennedy-Darling, Ph.D. Spatially defined immune cell distribution within tumor microenvironments before and after PD-L1 inhibitor treatment Vincent Christopher Luca, Ph.D. Deconstructing the structural mechanisms of cytokine-mediated JAK activation Roy Louis Maute, Ph.D. Characterization of the MHC/ LILRB signaling axis as an immunotherapeutic target in cancer Monica M. Olcina, Ph.D.* Innate immunity and cancer: Targeting the complement system to improve treatment response Qian Yin, Ph.D.* Activation of endogenous anergic self-specific CD8+ T cells by polymeric nanoparticles for enhanced cancer immunotherapy Lloyd J. Old Memorial Fellow Uniformed Services University of the Health Sciences, Bethesda, MD Maria K. Traver, Ph.D. Macroautophagic control of lymphocyte activation and proliferation University Health Network, Toronto, Canada Christian Bassi, Ph.D.* Role of HMGB1 in breast cancer resistance to chemotherapy Zhenyu Zhong, Ph.D. Identification of key immune homeostatic regulators that control obesity-induced liver inflammation and disease Maureen Ann Cox, Ph.D. Investigation of the role of HMGB1 in asbestos-driven inflammation and mesothelioma development Yina Zhu, Ph.D. Mechanisms that underpin the sequestration of the tumor suppressor ebf1 at the nuclear lamina University of California, Berkeley, Berkeley, CA Michele Ardolino, Ph.D. MHC-deficient tumors inactivate infiltrating natural killer cells: A new target for cancer immunotherapy Olivia Majer, Ph.D. Dysregulated Toll-like receptor responses as an oncogenic driver April Price, Ph.D. Expression and function of Toll-like receptors in intestinal epithelial cells University of California, San Diego, La Jolla, CA Sascha H. Duttke, Ph.D. Reprogramming macrophage phenotypes during immunosurveillance and neoplastic progression Bengt Martin Gustavsson, Ph.D. Structural basis of CXCR7 ligand binding and signaling Robertson Foundation Fellow Hyang-Mi Lee, Ph.D. Targeting regulatory T cellmediated regulation of IFNγy-driven anti-tumor immunity Shabnam Shalapour, Ph.D. Development of immunosuppressive plasma cells that interfere with T celldependent immunogenic cancer chemotherapy The University of Chicago, Chicago, IL Leticia Corrales, Ph.D. Study of the regulation of the STING/IFNβ pathway by the inflammasome/IL-1 pathway and its effect in the anti-tumor T cell response Stefani Spranger, Ph.D. The role of tumor-intrinsic oncogene alterations in immune evasion of melanoma University of California, San Francisco, San Francisco, CA Hsin Chen, Ph.D. Mechanisms controlling lymphocyte retention in and egress from tissue University of Minnesota, Minneapolis, MN David Lampi Hermanson, Ph.D. Chimeric antigen receptordirected natural killer cellular immunotherapy Adam H. Courtney, Ph.D. Elucidation of Lck feedback mechanisms Robertson Foundation Fellow Pamela C. Rosato, Ph.D.* Harnessing tissue resident memory T cells to combat solid tumors Brian R. Graziano, Ph.D. Using optogenetics to probe the in vivo biochemistry of cell movement Adam J. Litterman, Ph.D. A global map of mRNA regulatory elements in CD8+ T cells Edward W. Roberts, Ph.D. Lifespan, fate, and function of immune cells educated in primary tumors University of Oxford, Oxford, United Kingdom Nathan West, Ph.D. Analysis of novel susceptibility genes in chronic intestinal inflammation and colon cancer The University of Texas MD Anderson Cancer Center, Houston, TX Ka Ho Stephen Mok, Ph.D.* Effects of anti-CTLA-4 and anti-PD-1 on memory T cell differentiation Xiaolei Su, Ph.D. Mechanisms underlying the dynamic organization of T cell microclusters Eugene V. Weissman Fellow Adam Williamson, Ph.D. Activation of corpse engulfment to alleviate tumor-induced neurotoxicity The University of Texas Southwestern Medical Center, Dallas, TX Tuo Li, Ph.D. Roles of mammalian cyclic dinucleotide signaling in cancer therapies Xiaojun Tan, Ph.D.* Phosphoinositide regulation of STING trafficking and cancer immunity CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 21 Haidong Tang, Ph.D. Tumor-specific LIGHT targeting for cancer immunotherapy University of Washington School of Medicine, Seattle, WA Jonathan M. Clingan, Ph.D. Integration of transcriptional and translational control of the antiviral response Elizabeth Gray, Ph.D. Functional analysis of the interferon stimulatory DNA pathway Marc Joseph Lajoie, Ph.D.* Protein nanoparticles to elicit defined T cell response against cancer cells University of Wisconsin-Madison, Madison, WI Davalyn R. Powell, Ph.D. The role of neutrophils and CXCL8-CXCR1/2 signaling in glioblastoma cell invasion Vanderbilt University, Nashville, TN Katy Beckermann, M.D., Ph.D.* Metabolic barriers to T cell function and immunotherapy in renal cell carcinoma Merck Fellow NIR HACOHEN, PH.D. Washington University School of Medicine, St. Louis, MO Jennifer K. Bando, Ph.D. Immune modulation of dormant skin tumor development and persistence Matthew M. Gubin, Ph.D. Using genomics to identify targets of checkpoint blockade cancer treatment and to identify optimal target antigens for vaccination Whitehead Institute for Biomedical Research, Cambridge, MA Yang Eric Guo, Ph.D. Biogenesis and regulatory functions of super-enhancer RNAs in cancer cells of the immune system Giulia Pasqual, Ph.D. In vivo tracking of B cell-T cell interactions in the germinal center Mohammad Rashidian, Ph.D. Non-invasive imaging of immune responses for early detection of cancer and to monitor immunotherapy Kehui Xiang, Ph.D.* Investigate the importance and mechanism of poly(A) tail lengthmediated translational control in different immune cells Yale University School of Medicine, New Haven, CT Najla Arshad, Ph.D. The effect of tumor-associated mutant calreticulin on antigen presentation and tumorigenesis Will H. Bailis, Ph.D. Identification and characterization of immune escape mechanisms in leukemia Guoliang Cui, Ph.D. The influence of nutrient availability in the tumor microenvironment on CD8+ T cell survival and function Ruth A. Franklin, Ph.D. The role of macrophages in tissue homeostasis and tumor progression Donald J. Gogel Fellow Nicola Gagliani, Ph.D. Targeting Th17 cell plasticity to control colorectal cancer development Dr. Keith Landesman Memorial Fellow Noah Wolcott Palm, Ph.D. Role of helminth infections and the commensal microbiota in intestinal inflammation Debrup Sengupta, Ph.D. Membrane trafficking events regulating cross presentation INVESTIGATOR AWARDS Four-year bridging grants to assistant professors undertaking their first independent investigations in basic and tumor immunology, designed to provide flexibility and stability while they establish their laboratories. Liang Zhou, M.D., Ph.D. Northwestern University, Chicago, IL Molecular mechanisms of action of Ahr in T cell differentiation and function CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP) Two-year grants that provide catalytic support for translational laboratory studies designed to answer new scientific questions that arise in the clinic, with special focus on improving immunotherapy for cancer patients. Austin Health/Ludwig Cancer Research, Melbourne, Australia Jonathan S. Cebon, Ph.D., FRACP Evaluation of ROPN and SPANX as targets for antigen-specific immunotherapy Wade F.B. Thompson Investigator Brigham and Women’s Hospital/ Harvard Medical School, Boston, MA Niroshana Anandasabapathy, M.D., Ph.D.* Actioning a newly-defined target of peripheral tumor-immune surveillance in dendritic cells Broad Institute of MIT and Harvard, Cambridge, MA Nir Hacohen, Ph.D. Unbiased single cell analysis of the lung tumor microenvironment to understand failure modes of checkpoint blockade inhibitors Wade F.B. Thompson Investigator Cancer Research Center of Toulouse Purpan, Toulouse, France Roland S. Liblau, M.D., Ph.D. EVER proteins: Immune control of skin infection by beta-human papillomaviruses and skin cancer Columbia University Medical Center, New York, NY David M. Owens, Ph.D. Therapeutic targeting of intrinsic T cell suppression during anti-tumor immunity Dana-Farber Cancer Institute, Boston, MA Michael Goldberg, Ph.D. Use of CRISPR/Cas9 platform to improve function of cytotoxic T lymphocytes against melanoma Fondazione Centro San Raffaele, Milan, Italy Matteo Bellone, M.D. Combining adoptive T cell therapy to tumor vessel targeting and checkpoint blockade for cancer therapy Icahn School of Medicine at Mount Sinai, New York, NY Nina Bhardwaj, M.D., Ph.D.* Analysis of immune responses induced by in situ, autologous therapeutic vaccination against solid cancers with intratumoral Poly-ICLC (Hiltonol®) Joshua Brody, M.D. Understanding a novel in situ lymphoma vaccine: Neoantigen discovery with whole exome sequencing and neoantigenreactive T cell checkpoint molecule profiling with CyTOF La Jolla Institute for Allergy and Immunology, La Jolla, CA Stephen P. Schoenberger, Ph.D. Exome-guided neoantigen discovery and validation in head and neck squamous cell carcinoma Leiden University Medical Center, Leiden, The Netherlands Ferry A. Ossendorp, Ph.D. Novel vaccine nanoformulations for clinical mutanome-based cancer immunotherapy Massachusetts General Hospital, Boston, MA Rakesh K. Jain, Ph.D. Improving immunotherapy for metastatic breast cancer via normalization of the tumor microenvironment Andrew D. Luster, M.D., Ph.D.* Targeting the CXCR3 chemokine system to improve anti-PD-1 immunotherapy Mayo Clinic, Rochester, MN Haidong Dong, M.D., Ph.D. Monitoring T cell responses during anti-PD-1 therapy Medical University of South Carolina, Charleston, SC Mark P. Rubinstein, Ph.D.* Generating human tumor-reactive T cells with high levels of IL-2Rα for adoptive T cell therapy Memorial Sloan Kettering Cancer Center, New York, NY Alexander Y. Rudensky, Ph.D. Immunoregulatory correlates of a phase I/II study of mogamulizumab in subjects with advanced and/or metastatic solid tumors Genentech Investigator Northwestern University, Chicago, IL Derek A. Wainwright, Ph.D.* IDO1 in glioblastoma: Translating work from mouse to man Wade F.B. Thompson Investigator NYU Langone Medical Center, New York, NY John Carucci, M.D., Ph.D. Targeting the immune system to treat aggressive squamous cell carcinoma Oregon Health & Science University, Portland, OR Amanda Lund, Ph.D. FasL-expressing lymphatic vessels in melanoma Osaka University, Osaka, Japan Hiroyoshi Nishikawa, M.D., Ph.D. Novel cancer immunotherapy targeting regulatory T cells by antiCCR4 monoclonal antibodies Ottawa Hospital Research Institute, Ottawa, Canada John C. Bell, Ph.D.* Bioengineering an oncolytic vaccinia virus to augment the antitumor immune response in human cancers QIMR Berghofer Medical Research Institute, Brisbane, Australia Mark J. Smyth, Ph.D., FAHMS The preclinical validation of CD96 as a checkpoint target for cancer immunotherapy Wade F.B. Thompson Investigator CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 23 University of Minnesota, Minneapolis, MN Bruce R. Blazar, M.D. Lymphoid organ repair after cancer therapy for improving anti-tumor immune responses University of Oxford, Oxford, United Kingdom Paul Klenerman, M.D., Ph.D. Licensing human mucosalassociated invariant T cells to kill hepatocellular carcinomas BRUCE R. BLAZAR, M.D. Saint Louis University School of Medicine, St. Louis, MO Ryan M. Teague, Ph.D. Defining the mechanisms of human T cell rescue by checkpoint blockade immunotherapy Stanford University School of Medicine, Stanford, CA Dean W. Felsher, M.D., Ph.D. Oncogene addiction and immune activation Holbrook E. Kohrt, M.D., Ph.D.† T cell biomarker development for effective immunotherapy for recurrent non-Hodgkin B cell lymphoma The University of Chicago, Chicago, IL Thomas F. Gajewski, M.D., Ph.D. Identification of tumor-intrinsic signaling pathways that inhibit host immune responses as potential therapeutic targets to expand the applicability of immunotherapy Oliver R. Grace Investigator The University of Melbourne, Melbourne, Australia Jose A. Villadangos, Ph.D. Characterization and prevention of “stunning,” a cytotoxic T lymphocyte inactivating program that impairs adoptive cell therapy against cancer UCLA Medical Center, Los Angeles, CA Roger S. Lo, M.D., Ph.D. Determinants of responses to anti-PD-1/PD-L1 therapy and its combination with BRAF/MEK co-targeting in melanoma Wade F.B. Thompson Investigator Universidad Autónoma de Madrid, Madrid, Spain Bruno Sainz Jr., Ph.D. Role of the innate immune system in promoting cancer stem cells University Health Network, Toronto, Canada Tak W. Mak, Ph.D., D.Sc., F.R.S.C.* Evaluating the role of Tosomediated inflammation in anti-tumor responses University Hospital of Lausanne, Lausanne, Switzerland Daniel E. Speiser, M.D. Identification and validation of new targets for cancer immunotherapy in “exhausted” anti-cancer CD8+ T cells from mice and humans University of California, San Francisco, San Francisco, CA Markus Muschen, M.D., Ph.D.* Targeted hyperactivation of B cell receptor signaling to amplify therapeutic responses to CART19 treatment University of Southern California, Los Angeles, CA W. Martin Kast, Ph.D. Anti-CTLA-4 immune modulation following chemoradiation in cervical cancer patients The University of Texas MD Anderson Cancer Center, Houston, TX Michael A. Curran, Ph.D.* Hypoxia drives tumor immune suppression and immunotherapy resistance University of Virginia Health System, Charlottesville, VA Craig L. Slingluff Jr., M.D. Retention integrins: Induction and function on cancer-reactive T lymphocytes Wade F.B. Thompson Investigator Vanderbilt University, Nashville, TN Jeffrey C. Rathmell, Ph.D. Metabolic immunosuppression of T cells in clear cell renal cell carcinoma and anti-PD-1 therapy Wade F.B. Thompson Investigator Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia Nicholas David Huntington, Ph.D.* Development of a checkpoint inhibitor that targets the intracellular protein CIS to enhance natural killer cell anti-tumor immunity Washington University School of Medicine, St. Louis, MO Gavin P. Dunn, M.D., Ph.D.* Monitoring the anti-tumor immune response in glioblastoma patients treated with a personalized neoepitope vaccine Weill Cornell Medicine, New York, NY Juan R. Cubillos-Ruiz, Ph.D.* Targeting LPA sensors in the tumor microenvironment to enhance ovarian cancer immunotherapies Wade F.B. Thompson Investigator Yale School of Medicine, New Haven, CT Susan M. Kaech, Ph.D. Enhancing immunotherapy-based cancer treatments through CD40dependent immunomodulation of the tumor microenvironment Wade F.B. Thompson Investigator COORDINATED CANCER INITIATIVES Funding for research in specified cancer areas deemed able to provide clinically relevant insights and discoveries with the potential to accelerate development of cancer immunotherapies. Centre de Lutte Contre Le Cancer Nantes-Atlantique, Nantes-Saint Herblain, France Danila Valmori, Ph.D. Vaccination strategies for the treatment of epithelial ovarian cancer Icahn School of Medicine at Mount Sinai, New York, NY Hearn Jay Cho, M.D., Ph.D. Vaccine immunotherapy program in multiple myeloma Institut Gustave Roussy, Villejuif, France Maha Ayyoub, Ph.D. Role of the gut microbiota in the ontogeny and homeostasis of regulatory CD4+ T cells and in their alteration along immune responses to ovarian cancer CLINICAL ACCELERATOR The Clinical Accelerator brings together the best capabilities of the world’s leading academic researchers, drug companies, and a unique nonprofit venture fund to kick-start the development of powerful new treatments for cancer patients. To view a list of all current sites and lead investigators, go to page 53. CLINICAL STRATEGY TEAM GRANTS Team Leads: Nina Bhardwaj, M.D., Ph.D., and Sacha Gnjatic, Ph.D. Investigators: Eric Schadt, Ph.D., Rachel Sabado, Ph.D., Matthew D. Galsky, M.D., Icahn School of Medicine at Mount Sinai, New York, NY The mutation-derived tumor landscape of advanced bladder cancer: A platform to optimize cancer immunotherapy Team Lead: John C. Herr, Ph.D.† University of Virginia Health System, Charlottesville, VA Investigators: Victor Engelhard, Ph.D., Craig Slingluff, M.D., and Timothy Bullock, Ph.D., and Mark Kester, Ph.D., University of Virginia Health System, Charlottesvillel, VA; Jamal Zweit, Ph.D., Virginia Commonwealth University, Richmond, VA Immunotherapeutic targeting cell surface neoantigen SAS1B (Ovastacin, ASTL) Team Lead: Andrew Sikora, M.D., Ph.D., Baylor College of Medicine, Houston, TX Investigators: Sacha Gnjatic, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY; Christine Chung, M.D., Moffitt Cancer Center, Tampa, FL; Nham Tran, Ph.D., University of Technology, Sydney, Australia; Cornelis J.M. Melief, M.D., Ph.D., Leiden University, Leiden, The Netherlands Targeting the tumor immune microenvironment to enhance immune-stimulating effects of chemoradiotherapy Team Lead: Mark J. Smyth, Ph.D., FAHMS, QIMR Berghofer Medical Research Institute, Brisbane, Australia Investigators: Scott J. Antonia, M.D., Ph.D., Moffitt Cancer Center, Tampa, FL; Georgina V. Long, Ph.D., M.B.B.S., and Richard Scolyer, M.B.B.S., M.D., Melanoma Institute of Australia and University of Sydney, Sydney, Australia; John Stagg, Ph.D., University of Montréal, Montréal, Canada Targeting adenosine in the tumor microenvironment Team Leads: Hassane M. Zarour, M.D., and John M. Kirkwood, M.D. Investigators: James J. Lee, M.D., Mark A. Socinsky, M.D., Adam M. Brufsky, M.D., Ph.D., University of Pittsburgh School of Medicine, Pittsburgh, PA; Alan J. Korman, Ph.D., Bristol-Myers Squibb, Redwood City, CA Targeting multiple inhibitory receptors in cancer patients Team Leads: Hideho Okada, M.D., Ph.D., and Lawrence Fong, M.D., University of California, San Francisco, San Francisco, CA Investigators: Robert P. Edwards, M.D., Pawel Kalinski, Ph.D., University of Pittsburgh School of † Deceased Medicine, Pittsburgh, PA; Kunle Odunsi, M.D., Ph.D., Roswell Park Cancer Institute, Buffalo, NY Enhancing T cell homing to solid cancers by stimulating proper chemokines CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 25 Team Lead: Lei Zheng, M.D., Ph.D., Investigators: Elizabeth Jaffee, M.D., Eric Lutz, Ph.D., Todd Armstron, Ph.D., Johns Hopkins University School of Medicine, Baltimore, MD Tipping the balance in the tumor microenvironment as a next generation platform for pancreatic cancer immunotherapy CLINICAL TRIALS FUNDED A first-in-human single ascending dose study of TRX518 in subjects with unresectable stage III or stage IV malignant melanoma or other solid tumor malignancies • Henry Koon, M.D., University Hospitals, Cleveland, OH • Dale Shepard, M.D., Ph.D., Cleveland Clinic, Cleveland, OH • Jedd D. Wolchok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY An open label, phase I study of a neoantigen vaccine (TESLA-001), with a checkpoint inhibitor, in patients with metastatic cancer* • Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY • Gavin Dunn, M.D., Ph.D., Washington University School of Medicine, St. Louis, MO A phase I study of NY-ESO-1 vaccine in combination with ipilimumab in patients with unresectable or metastatic melanoma, for whom treatment with ipilimumab is indicated • Jonathan S. Cebon, Ph.D., FRACP, Austin Health/Ludwig Cancer Research, Melbourne, Australia • Craig E. Devoe, M.D., North Shore LIJ, North Shore University Hospital, Manhasset, NY • Philip Friedlander, M.D., Icahn School of Medicine at Mount Sinai, New York, NY • Michael A. Postow, M.D., Memorial Sloan Kettering Cancer Center, New York, NY • Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA • Hussein Tawbi, M.D., Ph.D., University of Pittsburgh Cancer Institute, Pittsburgh, PA Phase I study to assess safety and tolerability of tremelimumab and durvalumab, administered with high dose chemotherapy and autologous stem cell transplant * • Hearn Jay Cho, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY • Alexander M. Lesokhin, M.D., Memorial Sloan Kettering Cancer Center, New York, NY A phase I study to evaluate the safety and tolerability of antiPD-L1, durvalumab, in combination with tremelimumab in subjects with advanced solid tumors • Kunle Odunsi, M.D., Ph.D., AnnaMaria Kellen Clinical Investigator, Roswell Park Cancer Institute, Buffalo, NY • Patrick Ott, M.D., Ph.D., Dana-Farber Cancer Institute, Boston, MA • Jedd D. Wolchok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY A phase I/II dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies * • Dmitriy Zamarin, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY A study of ALK inhibitor, ensartinib, and anti-PD-L1, durvalumab, in subjects with ALK-rearranged non-small cell lung cancer/a phase I/II study of combination immunotherapy and mRNA vaccine in subjects with non-smallcell lung cancer (NSCLC) • Leena Gandhi, M.D., Ph.D., NYU Langone Medical Center, New York, NY TRIALS SUPPORTED WITH REAGENTS A phase I/II study of in situ vaccination with tremelimumab and IV durvalumab plus PolyICLC in subjects with advanced, measurable, biopsy-accessible cancers * • Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY • Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA A phase I open label, multicenter, multi-ascending dose trial evaluating the safety, tolerability, and immunogenicity of intramuscular recombinant NY-ESO-1 protein with GLASE adjuvant in patients with unresectable or metastatic cancer expressing NY-ESO-1 • Immune Design, Seattle, WA A phase II study to evaluate the clinical efficacy and safety of standards of care in combination with checkpoint blockade in patients with glioblastoma* • David A. Reardon, M.D., Dana-Farber Cancer Institute, Boston, MA Phase I/II study of chemoimmunotherapy with Toll-like receptor 8 agonist motolimod and checkpoint blockade in subjects with recurrent, platinumresistant ovarian cancer for whom pegylated liposomal doxorubicin is indicated • George Coukos, M.D., Ph.D., University Hospital of Lausanne, Lausanne, Switzerland A multi-peptide vaccine plus Tolllike receptor agonists in melanoma patients, with evaluation of the injection site microenvironment for resected stage IIB-IV • Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA A phase I study of cancer vaccine CHP-NY-ESO-1 in combination with Poly-ICLC in patients with esophageal cancer or malignant melanoma expressing NY-ESO-1 • Hiroshi Shiku, M.D., and Shinichi Kageyama, M.D., Mie University School of Medicine, Mie, Japan A phase I study of concomitant WT1 analog peptide and NY-ESO-1 • David O’Malley, M.D., The Ohio State University Wexner Medical Center, Columbus, OH • Paul Sabbatini, M.D., Memorial Sloan Kettering Cancer Center, New York, NY A phase I study of vaccination with NY-ESO-1 protein mixed with Poly-ICLC, OK-432 (Picibanil®), and ISA-51 (Montanide®) in patients with advanced cancers expressing NY-ESO-1 • Yuichiro Doki, Ph.D., and Hisashi Wada, M.D., Ph.D., Osaka University, Osaka, Japan A phase IA/IB study of vaccination with NY-ESO-1 protein, Poly-ICLC, and mogamulizumab in patients with adult T cell leukemia/ lymphoma expressing NY-ESO-1 • Yuzuru Kanakura, Ph.D., and Hiroyoshi Nishikawa, M.D., Ph.D., Osaka University, Osaka, Japan A phase II open label randomized study of Poly-ICLC-matured dendritic cells as an adjuvant for NY-ESO-1 and MELANA/MART-1 peptide vaccination compared to Montanide ISA-51 in patients with melanoma • Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY A pilot study of a novel multimodality immunochemotherapy platform for patients with advanced cutaneous T cell lymphoma • Catherine M. Diefenbach, M.D., NYU Langone Medical Center, New York, NY A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus PolyICLC in stage IB-IIIA breast cancer • Patrick M. Dillon, M.D., University of Virginia Health System, Charlottesville, VA A preclinical mouse vaccination experiment to compare the effectiveness of Poly-ICLC to that of the more common QS-21 • Samuel Danishefsky, Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY A trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus novel adjuvant combinations • Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA LEENA GANDHI, M.D.,PH.D. Evaluation of safety and immunogenicity of a multiphosphapeptide vaccine plus Poly-ICLC in participants with melanoma • Victor H. Engelhard, Ph.D., and Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA General research purposes (Poly-ICLC) • Fathia Mami-Chouaib, Ph.D., Institut Gustave Roussy, Villejuif, France General research purposes (Poly-ICLC) • OncoPep, Inc., North Andover, MA Phase I study of NY-ESO-1 protein + Poly-ICLC +/- Montanide® ISA-51 VG vaccine in patients with advanced malignant melanoma • Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 27 Phase I/II trial of a long peptide vaccine (LPV8) + Toll-like receptor agonists for resected stage IIB-IV • Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA Role of Toll-like receptor 3 in macrophage-mediated programmed cell removal of tumor cells • Irving Weissman, M.D., Stanford University School of Medicine, Stanford, CA Safety and immunogenicity of vaccination with XAGE1b long peptides combined with PolyICLC in patients with stage III/IV pulmonary adenocarcinoma • Christian Taube, M.D., and Maarten L. Zandvliet, Ph.D., Leiden University Medical Center, Leiden, The Netherlands CARL H. JUNE, M.D. CORRELATIVE AND LABORATORY STUDIES Maha Ayyoub, Ph.D., Institut Gustave Roussy, Villejuif, France Early-phase NY-ESO-1 clinical trials in patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and monitoring of tumor-specific immune responses Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY, and Anna C. Pavlick, D.O., NYU Langone Medical Center, New York, NY Phase II study of CTLA-4 blockade and low dose cyclophosphamide in patients with advanced malignant melanoma after failure of at least one prior therapy Sacha Gnjatic, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY Immunological monitoring for Cancer Vaccine Collaborative trials Elke Jäger, M.D., Krankenhaus Nordwest, Frankfurt, Germany Core support for NY-ESO-1 clinical trials Daniel E. Speiser, M.D., University Hospital of Lausanne, Lausanne, Switzerland Vaccination of melanoma patients (stage II-IV) with ImmuFact IMP321, tumor antigenic peptides, and Montanide Danila Valmori, Ph.D., Centre de Lutte Contre Le Cancer NantesAtlantique, Nantes-Saint Herblain, France Early-phase NY-ESO-1 clinical trials in patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and monitoring of tumor-specific immune responses REAGENT MANUFACTURE Production of NY-ESO-1 overlapping peptides for use in a variety of trials PolyPeptide Laboratories San Diego, San Diego, CA Poly-ICLC stability testing Oncovir, Inc., Washington, DC LEVERAGED GRANTS Special partnerships to explore novel preclinical and clinical studies in high-priority research areas. James P. Allison, Ph.D., The University of Texas MD Anderson Cancer Center, Houston, TX, and Antoni Ribas, M.D., Ph.D., UCLA Medical Center, Los Angeles, CA Cancer Immunology Translational Research Dream Team: Immunologic checkpoint blockade and adoptive T cell transfer in cancer therapy In partnership with the Entertainment Industry Foundation/ Stand Up To Cancer Carl H. June, M.D., and Gregory L. Beatty, M.D., Ph.D. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA Mesothelin-specific chimeric antigen receptor (CAR) T cell therapy for pancreatic cancer In partnership with the Lustgarten Foundation DESIGNATED GRANTS Grants to support research projects and public education and awareness initiatives for which, in most cases, donors have specifically raised funds. American Association for Cancer Research* Collaboration on Cancer Immunology Research Timothy N.J. Bullock, Ph.D. University of Virginia Health System, Charlottesville, VA Enhancing immune therapy for brain metastases with focused ultrasound In partnership with the Focused Ultrasound Foundation George Klein, M.D., D.Sc.* Karolinska Institutet, Stockholm, Sweden Studies on Epstein-Barr virus oncogenes and tumor suppressor genes, tumor immunology, and inhibition of tumor cell growth by stroma cells In partnership with the Concern Foundation ANNUAL AWARDS In addition to providing financial support to researchers and investigators, CRI also honors scientists and community leaders with achievement awards. WILLIAM B. COLEY AWARD FOR DISTINGUISHED RESEARCH IN BASIC AND TUMOR IMMUNOLOGY Annual prize given to one or more scientists whose discoveries in the fields of immunology or tumor immunology contribute to the advancement of immune systembased therapies for cancer. Glenn Dranoff, M.D.* Novartis Institute for BioMedical Research, Cambridge, MA Alexander Y. Rudensky, Ph.D.* Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research, New York, NY FREDERICK W. ALT AWARD FOR NEW DISCOVERIES IN IMMUNOLOGY Prize honoring a former postdoctoral fellow in recognition of outstanding success in academia or industry for research that may have a potentially major impact on immunology. AACR-CRI LLOYD J. OLD AWARD IN CANCER IMMUNOLOGY Award recognizes an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field. Ronald Levy, M.D.* Stanford University, Stanford, CA In partnership with the American Association for Cancer Research OLIVER R. GRACE AWARD FOR DISTINGUISHED SERVICE IN ADVANCING CANCER RESEARCH Annual prize that recognizes the contributions of dedicated laypersons or organizations whose leadership has had a significant impact on cancer research. Kenneth C. Frazier* Chairman and CEO, Merck & Co. Lauren S. Veronis* Trustee, Cancer Research Institute, and Former President, Irvington Institute for Immunological Research Nina Bhardwaj, M.D., Ph.D.* Icahn School of Medicine at Mount Sinai, New York, NY Malcolm A.S. Moore, D.Phil.* Memorial Sloan Kettering Cancer Center, New York, NY The study of hematopoietic stem cells and progenitor populations in normal and cancer cells Gar Reichman Laboratory CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 29 FUNDRAISING Powering Progress to Save Lives E verything the Cancer Research Institute does to keep the momentum of scientific progress moving forward would not be possible without generous support from individuals, foundations, and corporations who are as passionate as we are to see an end to cancer as we know it. The outpouring of generosity has given us another record-breaking year of fundraising. Together, contributions to CRI from donors totaled $42.1 million last year—a signal of donor trust in CRI that will allow us to fund more research that translates into more lives saved. From the thousands of individuals who make personal donations, to the passionate Team CRI members who plan fundraising events or participate in major endurance events around the country, to the families who donate yearly in memory of a loved one, and our trustees who give generously of both their time and money, no gift to CRI goes unappreciated. These contributions continue to make a difference in the life of the organization and the impact of its work. $42.1 MILLION FROM CONTRIBUTIONS AND SPECIAL EVENTS 260+ TEAM CRI FUNDRAISING EVENTS When I ask my friends, family, and coworkers to support my fundraising efforts for CRI, I do so knowing that any gift, in any amount, is going to be used wisely, and ultimately will help us stop this terrible disease. Priyanka Sewhani Chair, CRI Young Philanthropists Council Top Individual Fundraiser, 2016 Answer to Cancer Cycling Event CRI CEO AND DIRECTOR OF SCIENTIFIC AFFAIRS JILL O’DONNELL-TORMEY WITH FORMER REVLON CEO LORENZO DELPANI AND REVLON AMBASSADORS OLIVIA WILDE AND HALLE BERRY; NBC TODAY SHOW HOST MATT LAUER AT THE THROUGH THE KITCHEN PARTY; SEVEN-YEAR-OLD SAGE DREW PICTURES OF ANIMALS TO RAISE FUNDS FOR CRI; TEAM CRI RUNNERS IN 2016 UNITED AIRLINES NEW YORK HALF MARATHON; ST. LOUIS-BASED T-SHIRT COMPANY, TEE TURTLE, RAISED MORE THAN $54,000 To read stories of CRI donors, visit cancerresearch.org/supporters CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 31 DONORS Supporting the Cause T he Cancer Research Institute’s ability to advance important science and facilitate the development of immunotherapies for all types of cancer is made possible through the generous support of our donors. Acknowledgments listed here reflect contributions of $1,000 and more made to CRI between July 1, 2015, and June 30, 2016. $1,000,000+ Bristol-Myers Squibb Anna-Maria and Stephen Kellen Foundation MedImmune, Inc. The Thompson Family Foundation $500,000 - $999,999 The Hearst Foundations, Inc. Merck Multiple Myeloma Research Foundation, Inc. $100,000 - $499,999 Merle S. Cahn Foundation Clinton Global Initiative Estate of Prudence Cometa Concern Foundation Rose Marie Craig Trust Mr. and Mrs. Maurice J. Cunniffe Fight Colorectal Cancer Genentech GlaxoSmithKline Oliver R. Grace Charitable Foundation Estate of Inez G. Koch The Ambrose Monell Foundation Revlon Mr. and Mrs. Brian Riano Estate of Gertrude Schelling Betsy and Paul Shiverick / Shelter Hill Foundation The Estate of John Strang The Wildflower Foundation, Inc. $50,000-$99,999 Amgen AstraZeneca Pharmaceuticals LP Estate of Stuart Sidney Bernard Mr. and Mrs. Edgar R. Berner Bloomberg Philanthropies Estate of Frederick J. Brand Jennifer L. Brorsen and Richard M. DeMartini Ann and Geoffrey O. Coley Estate of Salvatore Corsaro Debevoise & Plimpton LLP Estate of Ruth Engelberg Mr. and Mrs. Sean P. Fahey Georgia and Don Gogel Janet Greenfield and Peter L. Bloom Marlene Hess and James Zirin Marion Esser Kaufmann Foundation F.M. Kirby Foundation, Inc. Mr. and Mrs. Kenneth G. Langone Mr. and Mrs. Alexander P. Lynch The Honorable Colleen McMahon and Frank V. Sica Joan Meltesen Unitrust Andy and Tom Mendell Orinoco Foundation Mr. and Mrs. Andrew M. Paul Linda C. Pinkus Fund of the Community Foundation of New Jersey Regeneron Pharmaceuticals, Inc. Johanna and Lief D. Rosenblatt Jeanne and Herb Siegel Jane and James Stern Sharzad and Michael Targoff Tee Turtle LLC Mr. and Mrs. Andrew K. Tsai Diane and Tom Tuft Ueberroth Family Foundation Lauren and John Veronis Jim Weiss, W2O Group Peter Zhou $25,000-$49,999 Agenus, Inc. Baird The Jeanne E. and Jacob A. Barkey Memorial Fund WHITE OUT THE PLAZA EVENT Beazley Group Kenneth N. Borofsky Estate of Raymond V. Byrne Richard E. Capri Foundation Celldex Therapeutics, Inc. Clayton, Dubilier & Rice LLC Frederic R. Coudert Foundation Leslie and Bob Dahl Oliver S. and Jennie R. Donaldson Charitable Trust The John and Jenny Eckerson Family Foundation Albert Nathan Eisenberg Charitable Foundation Eli Lilly & Company The John and Christine Fitzgibbons Foundation Sophie Garafola Goldman Sachs Group, Inc. Herman B. Golub Charitable Trust Green Charitable Foundation, Inc. Mary Gurster Hagedorn Fund Jeffrey Hammerbacher Leonard Lauder Mr. and Mrs. Ronald S. Lauder Miltenyi Biotec, Inc. Estate of Jean Marie Newcomer Anna Oschwald Trust Perri Peltz and Eric Ruttenberg David M. Polen Retirement Plan Proceeds Trust Bruce C. Ratner Mr. and Mrs. Michael A. Roe Edmond J. Safra Foundation Edith M. Schweckendieck Trusts Elena and Scott Shleifer Wachtell, Lipton, Rosen & Katz The Wasily Family Foundation, Inc. $10,000-$24,999 James P. Allison, Ph.D. Dr. Eva Andersson-Dubin and Mr. Glenn Dubin Anonymous Ronit and Marc Arginteanu Fund Yacov Arnopolin Alixandra Englund Audiberti Rose M. Badgeley Residuary Charitable Trust Judy and Ron Baron Charles N. Bartunek Bonbright Family Foundation Trust Mr. and Mrs. Charles Bronfman Jeffrey A. Burki Mr. and Mrs. Russell L. Carson James M. Citrin Corning Incorporated Karen and Matthew Crews Mr. and Mrs. Glenn J. DeSimone Domain Associates, LLC Dr. and Mrs. Ronald I. Dozoretz Thea Duell and Peter Cook Thomas English Fribourg Family Foundation CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 33 I am so grateful for all the folks that are fundraising and actively raising awareness with the Cancer Research Institute, who are helping patients like me who, after failing all other clinical trials, are looking for the next option. Ariella Hodgkin lymphoma survivor treated with immunotherapy Estate of James Gagliano Mr. and Mrs. Victor Ganzi Ambassador Charles A. Gargano Gratis Foundation Joyce Green Family Foundation Heidi Greene and Michael Kluger Seth Grossman GuideVine Technologies The Marc Haas Foundation Mr. and Mrs. Talbot Hamilton Shirley & Burt Harris Family Foundation Hempleman Family Charitable Giving Fund The Hurlbert Family Foundation The Karev Foundation Joel J. Kassimir Megan V. Kearney and Paul Enright LabAnswer and Its Employees The Max, Malie, Dr. Leonard, and Bernice Laub Family Foundation Mr. and Mrs. Matt Lauer The Ralph and Ricky Lauren Family Foundation Dalia and Larry Leeds Estate of Mildred Leiffer Florence & Edgar Leslie Charitable Trust Estate of Francis R. Linden Gordon J. Linden Loncar Investments LLC The Longhill Charitable Foundation Inc Loon Point Foundation Larry L. Luing Family Foundation Albert Marino Nancy L. Mauro Mr. and Mrs. Wesley McDonald Estate of Sharon H. McGowan Emil and Toby Meshberg Family Foundation Inc. Morgan Stanley & Co. Mr. and Mrs. Richard P. Morgenstern Mr. and Mrs. Jacques C. Nordeman North State Cancer League Royce E. Oliver Jr. Pace, Inc. PDT, Inc. Mr. and Mrs. Jeffrey M. Peek Harlan Peltz The Research Foundation of CUNY Carlos Rodriguez-Pastor The Edward John and Patricia Rosenwald Foundation Hillary and Wilbur Ross Schaumburg Professional Firefighters BE Adolph & Ruth Schnurmacher Foundation, Inc. The Estate of Louise S. Schoenke Lori Squire Mr. and Mrs. Leonard N. Stern Walter and Louise Sutcliffe Foundation Michael Steven Swell Liz Whitney Tippett Foundation, Inc. Estate of Zelda M. Uthe Mr. and Mrs. Ronald G. Weiner, Perelson Weiner LLP Wells Fargo Robert D. Welsh Lally Graham Weymouth and Joseph M. Cohen Whiting Foundation The Wiggins Foundation, Inc. $5,000-$9,999 AbbVie Inc. Gino Adamo’s St. Joseph Dinner Dance Alexander and Johannes Charitable Fund Jane B. Allen California Fund of the Hugh J. Andersen Foundation Christopher Ankoviak Anonymous (6) Backman Research Foundation C.R. Bard Foundation Basin Holdings Mercedes T. Bass Charitable Corporation Curtis Bergan Cathie Black and Tom Harvey Mr. and Mrs. James C. Blair Franci J. Blassberg and Joseph L. Rice III Borderland 2 on Twitch The Henry W. Bull Foundation Pat and Gil Caffray Kevin Cook Mr. and Mrs. Richard Corey Mr. and Mrs. Skip Cressman Danem Foundation EisnerAmper LLP Frank M. Ewing Foundation, Inc. Mr. and Mrs. Carlos A. Ferrer Tom Franco Sam Friedman Steven M. Galbraith Mr. and Mrs. Nathan Gantcher Terrell Gates Cheryl & Edward S. Gordon Foundation J. Ira and Nicki Harris Family Foundation Rochelle and David A. Hirsch Foundation, Inc. Mr. and Mrs. William D. Hobbs Innovate International Intelligence & Integration, LLC Inovio Pharmaceuticals Mr. and Mrs. George Kaufman Richard and Suzanne Kayne Charitable Fund Rachel Rutherford Englund Knapp Mr. and Mrs. David H. Koch Dr. Donald Kuspit Charles and Margaret Levin Family Foundation Michael Litt Audra M. Liu W. Bruce Lunsford D. Scott Mackesy Mr. and Mrs. Christopher L. Marhofer Evan McDonald-Stewart Guillaume Mear Joseph Mitola Mitsubishi UFJ Securities (USA), Inc. Dr. and Mrs. Malcolm Moore Nandanson Charitable Foundation Newgen Strategies and Solutions, LLC NewLink Genetics Corporation Northfield Bank Morris W. Offit Parkell, Inc. Chris Parry Vickie and Rahn Pitzer Pluralsight Verne C. Powell Querrey Simpson Charitable Foundation The Raether 1985 Charitable Trust Geoffrey S. Raker Kristin and Michael Reed Family Foundation, Inc. Reed-Lane, Inc. Mr. and Mrs. Karl Roessner Daryl and Steven Roth Foundation Jami Rubin Peter Craig Russell Seaman Family Foundation Kevin W. Sharer Michael Charles Sharp Mr. and Mrs. Paul H. Sherry Mr. and Mrs. Brian Sir Mr. and Mrs. Craig Smith Geraldine and Ernest Smith Socket Telecom LLC Michael Sorensen Stainman Family Foundation Dr. David Staunton Mr. and Mrs. Allan Stern Mr. and Mrs. Douglas Stone Sharon and Tom Teles The Thom Family Foundation, Inc. Elizabeth and Jim Tinsman Venables, Bell & Partners LLC Paul H. Volpe Revocable Trust Jeff Webb Harriet and Ronald Weintraub Mr. and Mrs. James C. Zelter $1,000-$4,999 24-7 Auto Transport, Inc. Qasim Abbas Richard Abbey Debbie H. Abbott Kedar Abhyankar Abbey and Richard Aborn Johnson Abraham Accenture Mr. and Mrs. Lawrence N. Ackley John E. Adams ADI Meetings & Events Mr. and Mrs. Anthony Aellen AeroDyn Wind Tunnel LLC Frank Alberico John Alexander Patrick Allare Louise Allchin AllianceData Allied World Assurance Company Jennifer Almeida Audrie and Todd Alsdorf Dr. Amy Alspach American Hospice Foundation American Life Group Richard Ammerman Tom Ampeliotis Mr. and Mrs. Dale P. Anderson Robert G. Andrews Anonymous (35) Imane Anys Fadi Arbid Ariel Capital Management, LLC Garo H. Armen, Ph.D. Henry Arnhold Jan Aronson ASA Research Mr. and Mrs. Joseph Azara Jr. Michael Babiarz Katherine and Mark Babin Darius Babusis Kevin Baca Frederico Bandini Mr. and Mrs. Joseph Bank Charles B. Banks Brett Barganz David Baron The Barrington Foundation, Inc. Pamela S. Barry, Ph.D., and Thomas W. Schneider, Ph.D. Mary and Thomas Bartlett Stephen J. Bastone Mr. and Mrs. Neil Bayer Robbie and Ted Beaty Beckman-Matsui Family Foundation Mr. and Mrs. Everett A. Bell THE DONNY G MEMORIAL GOLF TOURNAMENT CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 35 Bell Forest Products Kathleen Belsten Joanne Benedict Mr. and Mrs. Jonathon Berezinski The Berkowitz Family Foundation Edward Bermas Adler Bernard Mr. and Mrs. Mark Berry Scott M. Besaw Bethel Park School District Mr. and Mrs. Larry D. Billen Gino V. Birbiglia The Birchwood Country Club Incorporated Mr. and Mrs. James W. Bishop Jr. Sharon and David Bishop Carol Biuso Burke Black Mr. and Mrs. James A. Block Kelly and Steve Bloom Theodore Blumenthal Stuart H. Bohart Barnabas Boon Ted J. Boulanger Trust Sylvia Bower Lisa and David Boyle BP Foundation, Inc. Brandt & Hochman Literary Agents, Inc. Marie Brenner and Ernest Pomerantz Samuel Bretheim Patrick Brett Bridges Family Charitable Fund Christian W. Brinkman Louis J. Briskman Jess Brown Judith S. and David B. Brown William E. Brown Mr. and Mrs. Mike Brzozowski Carla J. Buck Kathy D. Buehne Mr. and Mrs. Gregory A. Buhl Chris Burell Mr. and Mrs. Tom Burman Caesars Enterprise Services LLC Mr. and Mrs. John Calicchio The Campbell Family Eileen Campbell and Struan Robertson Mr. and Mrs. Rohn Campbell Antonio Campo Jennifer Cardettino and Andrew Hite Virginia and Edward Caress Family Fund Harold Carr Mr. and Mrs. Robert A. Carter Mr. and Mrs. Patrick Cassidy The Cayuga Foundation Dr. Jacob M. Chacko Dr. David R. Chapman Patrick Chapman Rory Chapple Kevin Charlton Jenchi Chen Kurtis Cicero Eleanor Clain-Stefanelli Mr. and Mrs. Daniel K. Clark Suzette Clayton Clean Slate Media Mr. and Mrs. Rodney Cobb Steve Cohen Michael J. Cohn James Coil Jean P. Colaco Michael Cominotto Anna Condo Kevin Conway Bob Cooper CeCe Cord Mr. and Mrs. Ronald Couture Mr. and Mrs. James R. Coyle CPAs 4 MDs, PA Craigslist Charitable Fund William S. Credle Mr. and Mrs. Christopher J. Creed D. Kirk Cromer Crossler Middle School Zoe Cruz CSX Transportation Lori Cuisinier and Anthony Hoberman The Randi and Roger Cunningham Charitable Fund Mr. and Mrs. John R. Curtis Jr. Cushman Family Foundation The Wayne and Nicole Cypen Philanthropic Fund at the Miami Foundation Thomas Daly Mr. and Mrs. Barrie M. Damson Mr. and Mrs. Timothy Danaher Munir Dauhajre Mr. and Mrs. Jason Davenport Gregory J. Davies Ashley N. Davis Mr. and Mrs. Gary Davis Mr. and Mrs. Roberto de Guardiola Nathalie and Charles de Gunzberg Christina De Mi Randa Dedicated Defined Benefit Services, LLC Della Calce Private Foundation, Inc. Emily and Rutger deQuay Mr. and Mrs. Paul Dertien Devonwood Foundation Sam C. Dicker Mr. and Mrs. Andrew Dickman Mr. and Mrs. Michael D. Dillon Katherine Dines Mr. and Mrs. John H. Dobbins Mr. and Mrs. Dennis R. Dodson Mr. and Mrs. Scott A. Dondershine Michael Donohue Scott Dressler Marie Dudick Deborah Dumaine Nancy P. Durr Melinda Edelcup Christopher S. Edwards Mr. and Mrs. Stephen C. Elkin David Emanuel Ralph Enderby Survivors Trust Hiroaki Eto E. Joseph Evans Charitable Trust Dr. and Mrs. Anthony B. Evnin Mr. and Mrs. Benjamin Falchuk Mr. and Mrs. Thomas E. Falgout Madeleine Farragher Stephen P. Farrar Dean Fearing Andrew Fernandez Louise Egdorf Fescine Finneran Family Foundation Mr. and Mrs. Winston O. Fitzhugh John A. Flood Daniel Flores Thomas Foley Joshua Ford Fort Myers Broadcasting Co. Fortress Investment Group LLC ForYourParty.com Russell Frandin Ethan Frey - Brookshire Realty Barry Friedberg Scott Friedman Jonathan Gainsley Carolyn D. Gaites Neil Gallagher Danielle and David Ganek Deborah Garcia John A. Gardner Linda M. Gase The Estate of Fritz Gautschi GE Foundation Genomic Health, Inc. Mohsen Ghaneian Marlene Gillis Kenneth Giuriceo Mr. and Mrs. David Glendinning Mr. and Mrs. Kenneth H. Globus Joseph Godley Victoria L. Goldberg Max Goldenberg Foundation Andrew Goldman Ellen M. Golub Charitable Foundation The Goodman-Lipman Family Foundation Inc. Dan L. Goodwin Gotham Color Ken Gottesman Mr. and Mrs. Jason Gottlieb Walter J. Grandfield Jillian Griffiths Aline and Richard Grimes Kathryn Grossman Guardians of Cridhe Mr. and Mrs. William M. Gutowitz HackerAgency Edward E. Haddock, Jr. Family Foundation Joshua D. Hall Troy Halterman Margaret H. Hamachek The Hampton Landing Co., LLC Adam D. Handwerker Mr. and Mrs. Lee M. Hanger Charlevoix County Community Foundation - Hanna Family Fund Mr. and Mrs. Robert Hanscom Estate of Victor E. Hansen Fleur and Leonard Harlan The Harris Family Charitable Fund Bethany Harris Eleanor and Steven Harris Mr. and Mrs. William B. Harrison Dr. and Mrs. William A. Haseltine Melinda Hassen Thomas Hassen Tyler Hassen Mr. and Mrs. Michael Haus Kathryn L. Haw THROUGH THE KITCHEN PARTY AT THE FOUR SEASONS RESTAURANT; ANSWER TO CANCER CYCLISTS; LABANSWER AND ITS EMPLOYEES CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 37 It was an honor to play a small role in the process that will sustain cancer immunotherapy into the future. Julian Suchman Team CRI runner, TCS New York City Marathon Mr. and Mrs. Robin Hayes Ms. Gale Hayman and Dr. Richard S. Bockman Head Family Trust Donald B. Hebb Jr. Margaret J. Heiser Alexandra B. Helms Tad R. Herz Beth Hickey Ed Hicks Higgins Charitable Trust James Higgins Reid T. Hironaga Dr. and Mrs. Frank Hoefflin Paul C. Hoehne Burt M. Hoffman Attorney At Law, LLC Christopher Hogan Hogan Lovells US LLP Jessica Holfman Lujan Kathleen and David Hollows HorrorHound Mr. and Mrs. Richard C. Hosley II Eric Howard John Howard Hudson Americas L.P. Kathleen Hughes Maritza Hurtado HzW Environmental Consultants Ideal Image of Delaware Capt. Scott Ingraham Integrus, LLC Mr. and Mrs. Marc J. Isaacs Mr. and Mrs. Seymour Israel E. Marion Jacknow Deborah and Arthur Jacobson The James Jacobson Family Fund Kate and Jeff Jaenicke George and Janet Jaffin Foundation Jakal Booster Club Janklow Foundation Elizabeth M. Jennings Tina Jicha Donald Joh Johri Family Charitable Foundation Anne and Johnny Jones Austin Jones JP Morgan Chase Foundation Rebecca and Michael Juneau Dr. Basim Kadhim Mr. and Mrs. Neil R. Kardos Mr. and Mrs. Howard Kaye Mr. and Mrs. Jerrel W. Kee Mr. and Mrs. Terry Keller Mr. and Mrs. William Keller Edna Kelley Veronica and Ray Kelly Mr. and Mrs. Richard Kerns Keurig Green Mountain Mr. and Mrs. Bradley D. Kevern Alena Kim Ken Kinslow William Kissling Mr. and Mrs. Brandon Kistler Mark E. Klein Jerry Kleinman Robert Klett Shannon Kline Koko Fitclub of Minnesota Miss Laine Koman Mr. and Mrs. Richard F. Kossik Takashi Kousaka Andrew Kratz John Krenicki Ivan Kriakov Brenda Kulick Mr. and Mrs. Kevin Kuntz Perry A. Kupietz Mr. and Mrs. David P. Kusel Mark Kwan Sheila Labrecque Mr. and Mrs. Benjamin Lambert Harlos R. Larrowe Laser Image Carey F. Lathrop The Jeremy Lau Fund Dr. Lena and Professor Peretz Lavie Martha and Drahomir Lazar The League of Legends Community Laura Ledford Elizabeth Lee Michelle Leeds Mr. and Mrs. Ben Lefkowitz Morris and Lillie Leibowitz Charitable Trust Mr. and Mrs. Craig Lemle David Lender Dr. and Mrs. Philip R. Lesorgen Mr. and Mrs. Francis L’Esperance Dr. Andrei Levin Richard and Emily Levin Foundation John S. Levy Mary Lynne Levy William Li Life Time Marketing, LLC Anthony Lin Tullia Lindsten, M.D., Ph.D., and Craig B. Thompson, M.D. Mr. and Mrs. Jerry Lis Daniel C. Litchfield Chris Lloyd Brad Loncar Heather Long Longboard Asset Management LLC Timothy and Leslie Lucas Charitable Fund William C. Lucia Brian Luing Donald L. Lundholm Peter Lyon Lynn E. Lyons Mr. and Mrs. Bruce R. MacDonald Macheist LLC Dr. Thomas Mack Robert S. Madden Madhatter’s Tea Party Thomas Maheras Chris & Melody Malachowsky Family Foundation Laurie and Jay Mandelbaum William Mansfield Mr. and Mrs. Michael Maranto Mariel Foundation Beverly and John Marino Jane Martin and Stuart Katz Mr. and Mrs. Redge A. Martin Mr. and Mrs. Steve Martin Richard A. Martini Martins Construction Corporation Michael M. Marzban Jeffrey A. Mason Mr. and Mrs. Allen R. Mass Dr. Philip Mastman Ellen C. Mathias John D. Mauro Jeffrey S. May Roy ‘Rem’ Mayes Dorothy McCabe and Lee Kuntz David McElligott Christopher McGarrigal Kate A. McKay Christine McKenney Robert M. McKeon Kelly McKernan Vincent McLaughlin Mr. and Mrs. Michael A. McMurphy Derek McTyier Medtronic Mehul Fund Richard Meier Foundation Susan F. Melson The Sue and Eugene Mercy, Jr. Foundation, Inc. Joan Meyers Michael Edwards Direct, Inc. Mr. and Mrs. Galem W. Millard Mr. and Mrs. Craig Miller Diane L. and Donald L. Miller Barry Minkoff Jahid Mirza Mr. and Mrs. John Mitchell Hiromasa Mizushima MJD Concepts, Inc. Esmail Mobarak Afshin Momtaz Gordon and Betty Moore Foundation Mr. and Mrs. Paul D. Moran Pauline K. Morgan Emily Morningstar Dr. Robert Moskowitz Erik Mouthaan Dr. Jason Much Mr. and Mrs. Bill Mullins Pamela Anne Murphy Vanitha Murugesan Maria Isabel Nadal De Puigdorfila Jenks Necker Charitable Fund Deborah Newsome-Smith Kevin K. Nickel Barbara Nielsen Jon Nite Norwalk High School Notre Dame Academy John Nowak Jeffrey Nuechterlein Brandon Nutter Rebecca and Douglas Obletz Melissa and Charles O’Brien Mr. and Mrs. Gregory A. Odle Christine Ogata Carolyn J. O’Hara Mr. and Mrs. James A. Olson Mr. and Mrs. John Orlando Daniel O’Shaughnessy Twila I. O’Sullivan Elma and Fred Otto Joe Oziel Packer Family Charitable Fund Michael Palmer Yvonne S. Palmer Dr. Vernon L. Pankonin Lee A. Paree Darryl L. Parrish Kelly and Gerry Pasciucco Lasantha Pathirana Joseph A. Patrick Foundation, Inc. Camilo Patrignani Patterson Companies Inc. China Pavilion Alan Petersen Jeffrey A. Peterson Dr. and Mrs. Frank Petitio Pew Charitable Trusts John C. Peyrebrune Ashley R. Piggush Mr. and Mrs. Patrick Pijanowski James Pinto Mr. and Mrs. Michael J. Pizzo Gerald Policastro William Pollock Ana Luisa Ponti Mr. and Mrs. Robert A. Posner Andrew W. Potash PPD Development, LP Austin J. Preslar Paul Pressler Mr. and Mrs. Michael J. Price T. Rowe Price Foundation, Inc. Puglisi Family 2014 Charitable Giving Fund Qualcomm Roberto Quarta Igor Rabin Races for Awareness Renate and Walter Rados James A. Randel Tammy and Eric Rasmussen Terrie L. Ray Reactive Systems Recover Painting, LLC Red Hat, Inc. Douglas Rediker Richard B. Reed Hulda and Michael Refermat Dawn E. Refsell Matthew Reischl Mr. and Mrs. Jerrid Rezin Chad E. Richman Kurt Riemenschneider Mr. and Mrs. Jonas J. Rieter Dr. Erika Riley Mr. and Mrs. David Riparbelli Mr. and Mrs. Herald L. Ritch Robert P. Rittereiser Anna Rockler Rebecca Rogers Dr. and Mrs. Leon Root Steven M. Rosenberg Fund Mrs. Abraham Rosenthal Jane Rosenthal and Craig Hatkoff Barry D. Roy Francois R. Roy Richard P. Royer Laurette Rup Robert Rushton MAKEUP ARTIST JESSICA HAZE CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 39 ANNUAL AWARDS DINNER AT THE METROPOLITAN CLUB; #WHITEOUTCANCER EVENT AT MEDIMMUNE/ASTRAZENECA; AND ANSWER TO CANCER CYCLING TEAM BRISTOL-MYERS SQUIBB The Rust Family Foundation Sallay Family Fund Stanley Saltzman Francine M. Sandoval Mr. and Mrs. Adarsh Sarma Rose Ann Scamardella Scanning America, Inc. Heather Schimmel Schluter Systems L.P. William O. Schmale Lauren A. Schmidt Rick Schnall Karen A. and Henry P. Schneider Mike Schoeben June and Paul C. Schorr III Dr. David N. Schrier Schulman Family Foundation Henry C. Schulte and Virginia M. Schulte Foundation Larry R. Schuneman James M. Scrivanich Brian Searcy Hooman Sedighi Mr. and Mrs. Thomas L. Seifert Karen Shapiro Stephen Shapiro Jane Sharp Dan Shedrick Cynthia Sheets Shell Oil Company Foundation Rocky John Sherer Raechelle B. Sherman Jonathan Shipman The Susan S. Shiva Foundation Showin’ for a Cure Mr. and Mrs. Brian D. Silverman Anne Silverstein Edward R. Simmons Simplistics, Inc. The Simpson Foundation Linda G. Singer Nate Sleeper Laura J. Sloate Lois V. Smigel Mr. and Mrs. Gordon H. Smith Mr. and Mrs. Jeffrey Q. Smith Mary F. Smith Family Foundation Nora M. Smith Patrick Smith Mr. and Mrs. Scott Sokol Mr. and Mrs. Howard Solomon Solutions By Design II, LLC Anne Spencer William Spero Michael Spitzenberger Kristen Sproat Colley St. Luke’s Lutheran Church Paul Stagg Edgar Stanley Bonnie M. and Robert J. Stapleton The Honorable and Mrs. Kenneth W. Starr Michael Starr Mary K. Steffens Foundation Beatrice Stern Patricia Stohler Bonnie and Tom Strauss Stuntz Family Foundation Mayo S. Stuntz Sweet/Polak Charitable Fund Marc Tabah Mr. and Mrs. Kok Chor Tan Jesyca Tang Joshua L. Targoff Nicki Taylor and the Cuddlebugs Jean and Kenneth Telljohann Tennis League Network, LLC Texarkana Jeep Junkies Club Mr. and Mrs. Jeffery Thomas Marc Thomson Thomson Reuters Mr. and Mrs. Andrew H. Tisch Dr. and Rev. David C. Tontonoz William Topham Mr. and Mrs. Alex Toppin Alain Tranchemontagne Mr. and Mrs. John Trousdale Paul Trunk TTX Company Mary Ann Tuft Timothy F. Turitto Allen M. Turner Dr. Lynn H. Turner USPA Liz Freel Classic Nancy and Jim Utaski Utility Contracting Co. Mr. and Mrs. Jeffrey K. Valentine Sr. Anne and Philip Vander Haar Csaba Vandor J.J. Venturini Village of Long Creek Maintenance Corporation The Villages Theater Company Millie Viqueira and Steven Miller VMware Foundation John Vogel Mr. and Mrs. Lance Volland The Kathleen B. and Charles R. Walgreen III Foundation Robert B. Walker Richard N. Walsh Barbara Walters Carrie L. Walworth Jeff Ware Joseph Warren Carolyn and David Wasserman Watermark Learning Sandra J. Wattier Web Decisions Group Steven E. Weigand The Weingarten Schnitzer Foundation Helen and Tom Welling Wendell Family Foundation S. Kyle Wesson Elizabeth G. Weymouth Gerald I. White The Wild Unknown David T. Wiley Joanna Williams Greg Wilson Patricia M. Wilson Mr. and Mrs. Dennis Winans Greg Wirth Michael J. Wisdom The Wise Family Trust Carole and Michael Witte Michael Woinsky Elaine and Jim Wolfensohn Gregg S. Wolpert Mr. and Mrs. William Worthington WowToyz Melissa Yannis-Grand Stephen Yegelwel Strauss Zelnick Zenith Ventures, Inc. J.L. Zrebiec Mr. and Mrs. Jeffrey Zucker Joan R. Zuckerman Marc Zuckerman Barry Zurbuchen Helen Coley Nauts Society The Helen Coley Nauts recognizes donors who have included the Cancer Research Institute in their estate plans. Through deffered gifts, bequests, trusts, and other planned giving instruments, these thoughtful individuals safeguard the Institute’s financial future. The Society is named in honor of Helen Coley Nauts, CRI’s founder. If you would like to learn more about making a planned gift, please contact Rupinder Kaur at [email protected] or (212) 688-7515. Estelle Abas Peter Adams Abigail Alderman Olga Aleskas Mildred E. Alexander Frederick E. Allard Edith M. Amateau Peggy Anderson Anonymous (6) Frances Antopol Freda S. Armstrong Grace Arnold Geneva A. Arthur Millie L. Arvanites Ruth Ascher Virginia and Rex Ashdown Lee Asher Belle Asherman Alice Auerbach Norman W. Austin Jeanne Avegno Else Baier Maureen and Charles Baker Olga Baker CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 41 Marion Balen Ella R. Banks Mary R. Baque Dorothy Barbeau Jeanne E. and Jacob A. Barkey Mr. and Mrs. Kenneth Barmore Connie Barnes William Barr Florence and Ben Barrack Rose Barrow Isabella Williams Bartholow and Bruce Burdette Bartholow Etta Baum Evelyn Beekman Frank L. Bell Germaine Benesch William A. Berkey Stuart S. Bernard Lucille Bernot Herta J. Bernstein Vincent L. Bessey Linda Bielat Grace M. Bishop John Bittel Guy Bjorkman Leslie J. Blain Anna H. Blankstein Paula J. Blatter Ruth Evelyn Bodbyl Eleanor Bodnar Ronald J. Bogus Nancy E. and Lawrence H. Bonander Mary Borbeck Rita Borenstein Robina C. Bouchard Ted J. Boulanger Trust Anna Isabel Boyd Hugh R. Boyd Barbara Brown Boyer Frederick Brand Joy B. Breidling Lucille Brents A. Arthur Bressman Brian M. Brewer Victor E. Broll Albert N. Brooks Minnie E. Brown Virginia Bruner Alfred R. Brunner Anne Luise Buerger Lucille A. Buland Mary C. Bundy Arthur Burkhardt Lois M. Burns and Robert W. Burns Dale T. Butterwick Joy Biggs Buttle Raymond V. Byrne Ann W. Calaski Marilyn and David Callahan Tracy Campbell Angelina Carbone Alfred Carlucci Julia Carlucci Pandora Rudland Carroll Donald O. Carswell Melba Case Mary Elizabeth Catto Doris M. Clanin William James Clapp Rodney Cobb William H. Coffee Bernice Cohn Gwendolyn Colburn Mr. and Mrs. Raymond Cole Edythe E. Coleman Bradley L. Coley Jr. Louis Comedy Prudence Cometa Phyllis L. Conley Vivian E. Conner and Ross I. Conner Lottie M. and Charles H. Cook Salvatore Corsaro Audrey Cowan Rose Marie Craig Eleanor H. Cromley Elmira Crosby Julia B. and John R. Curtis Vincent D’Amico Annabelle L. Danzig Carleen V. Davis Alice Dawes Aileen Adele De Long Eustis Dearborn Richard M. DeMartini Emma Deters Carolyn S. Detweiler Betty Disbrow Adelaide J. Dodge Sandford Dody Michael Dorner Mary Ann Draus Blanche Elizabeth Eckerts Rita Eggert Dorothy M. Eiser Earl R. Elliott Pauline E. Elliott Ralph Enderby Ruth Engelberg Valera L. Ennis Helen Epstein Nathan Epstein Max G. Eriksen Helen B. Esokait Florence L. and Ned A. Etkin Juanita M. Evans Mary S. Fadeley Helen Jean Falk Herbert Lynn Fann Barbara Feldman Robert I. Fendrich Carlos A. Ferrer Adelaide E. Ferris Louise Egdorf Fescine Elsie K. Filonchik Mary H. and Frances E. Flood Josephine Fonti Florence A. Forni Bernard W. Forrest Carole D. Franklin Clay Frazier Lucille O. French Alice M. Fried Anne Fruhner Lena Silverstein Fuhrman James Gagliano Gay H. Gahagan Zoltan Galdi Eugene G. Gallant Peter Gallant Mollie E. Gang Sophie Garafola Salvador Garcia Carole Gardner B.I. Garlinghouse Fritz Gautschi Thomas J. Gearing E. Yvonne and William O. Geisert Stella Gentile Mildred Gentry Penelope M. Georgiadis Mercedes C. Gerhard Patricia J. Getsfried Janet M. Gifford Regina Gilmour Steven D. Ginsberg Edna E. Glaessel Eleanor Goldberg Philip Goldblatt Raymond J. Gordinier Doris Gordon Jean R. and John G. Gosnell Norman Gottlieb Dorothy M. Graham E. Ruth Grant Annette and Owen Gray Bernice E. Grilleaux Floyd Dale Grisham Zoe S. Grove Noreen Bryce Gruebl Ronald J. Guglielmino Anna Guhring Marianne C. Hafner Jeanine Hair Nelle B. Haire Adrian Leroy Hall Diane Ham Mr. and Mrs. Virgil Hamby Frances E. Hanneman The Hansen Trust Lydia C. Hanson Loretta D. Hardy Mark L. Hariton Evelyn H. Harris Lori Harris Ottis C. Harris Helaine T. Harrison Yetta Hatch Anne M. Hauser James Leon Hawkins Margaret Hayman Clarence E. Hedberg Donald P. Heim Virginia Hemme Robert J. Hendry Fredrick Charles Henne Senora Henry Marion Hewett Kay Hilton Margot Hoffmann Nurine Hoke Eva M. Holmes Diane and Don Holmes Nellie Huff Grace M. Humphrey Mary L. Hutchins Idell E. and Fred W. Iltner Madeline Inguagiato Ruby R. Jankiewicz Lynn and Eldon Jasper Warren R. Jecklin Doreen and Basil Joffe Ruth Harvey Johnson Doris Kabat Rosemary Kaplan Sally J. Kaplan David Katz ANSWER TO CANCER CYCLING TEAM W2O; #WHITEOUTCANCER SUPPORTERS AT NBC TODAY SHOW PLAZA Sara Katz Bertha E. Kaufman Samuel Kay Blanche C. Kelly Jean Kemp Hugh W. Kennedy Mercedes E. Kent Elsie E. Kiel Corinne Kiell Theresa A. Kiely Mary B. Kilroe and Edward L. Kilroe Barbara Kincaide Hilda Kirson Shirlene Kisak Marilyn and Robert Klett Ruth and Hugo Klotz Anne Koch Inez G. Koch Truby Joy Kohl Mr. and Mrs. Harry Kompanek Juanita and Fred Koors Harry A. Kraus Mary T. Kraus Naomi P. Kruse Murray Kupferman Hiroko Kyuba Rose Lachow Sidney G. LaDue Anna Lagstein C. Linda Lambert Jewell Marie Lampkin Marguerite Landis CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 43 Louise G. Lane Caryl Lou Langford Elizabeth S. Larkin AnneMarie LaValle Mildred Leiffer Florence and Edgar Leslie Polly Annenberg Levee James F. Levens Frances Leventritt Betty Lou Levin Esther Levine Beatrice Levy Simon Lifshatz Francis R. Linden Harvey A. Linden Patricia A. Lindner George H. Lindskog Roseline Lissak Frances M. Lizak Johanna Loeb Ruby Q. Lokensgard Peter J. Lommen Bonnie Long Albie A. Adams Loving Madeline Lukowitz Mr. and Mrs. William H. Lyford Gertrude A. Lynch Hjordes Diane Lyttle Eleanor D. MacCracken Emilie Machalinski Catriona Macleod William S. Maddenborough David Madsen Henrietta Malbin Herbert J. Maletz Isabelle C. Malone Anna Malowany John Malowany Trust Ferne Magialardo Meyer Marcus B.M. Marinko Genevieve Martin Louemma Martin Lowell A. Martin Raleigh L. Martin Blanca Mattalia-Wyrzykowski Mildred G. Matz Donald Maurer Lourdes Mayuyu Margaret Mazzey Michael I. McBride Helen McCann Cecil McClernon Annette McDonald Sharon H. McGowan J. Donald McKinney Jr. Norma J. McPherson Jan Mears Grace Muriel Mecchi Joan Meltesen Nancy Jeanne Merkel Sidney Meskin Ethel L. Meyer Ezilda Michel Helen T. Middleton Dorothy Mae Miller William D. Miller Alex Mitchell Maha Mohamed Mr. and Mrs. Charles G. Moore Janet P. Morgan Maza D. Morris Louise and Peter Moseychuk Bryant A. Muenzen Alexander Munchweiler Irene R. and Martin F. Murphy Judith K. Murphy Kathryn T. Murphy Thomas P. Murray Naomi Myers Mayumi Nakagawa and John K. Lai Rita Nasser Alice A. Nauts Patricia Navarro Paula M. Neal Barbara Lynne Nelson Rose E. Nelson Jean Marie Newcomer Freda E. Newton and William E. Newton Herb H. Nichols Bernard R. Niewoehner Geneva W. Nolen Jacques C. Nordeman Mary M. Nowak Mary Nunez Dorothy B. Nurick Margaret M. and Harry A. Oak Nora Odets Arvilla Ogden Michele A. Ognibene Roselyn R. Olken Alice Orlich Mary O’Rourke Anna and Paul Oschwald Albert Ottinger Lily Pace and Floyd Pace Marjorie W. Packwood Erma N. Panfilio Andrew Reid Paton Eleanor T. Patterson Carmen F. Patti Foster Clae Patton Frederick V. Payne Nancy Elizabeth Pease April Peck Donald H. Peper Agnes Phelps Elizabeth F. Phillips John Piercy Harriet-Anne Pierson Rochelle Pinz Cynthia Joy Platt Dorothy Plumb Mabel Plunkett Nick J. Pokea David M. Polen Esther Posin Richard Potruch Despina Poulos Clifford Presky Joyce A. Prime Dorothy S. Pritchard Aspasia Radoumis Carol Diane Ranken James B. Ransohoff Esther Reed Harry Delos Reich Helen Relkin Floris J. Renk LaDonna Reynolds James F. Rice Florence V. Richardson Adam J. Richter Virginia L. Riddle Robert T. Ridley Michael Riley Adeline Ringeisen Dr. Fred Ringel Veronica A. Rose Susan Rosenberg Ilene Roth Leah Roth Moises Rubiano Dorothy and Ernest Rueppel Gloria Ruminsky Hedwig Salzer Margaret E. Sammons Lydia B. Scannell Gertrude Schelling Martha Schneller Louise S. Schoenke Virginia Schuettpelz Helen R. Schutt Ruth Schwartzman Rev. Harold Bend Sedgwick Dorothy K. Sefcovic Francine Segall Clara Senk Natalie Shebs Dorothy M. Sheese Margaret Sheets Donald Sherwood Renee and Irwin Shishko Laura M. Sidener Lottie Siegel Katherine U. Silva Belle V. Silverstein Augusta Simon Roma Sinclair Estelle Singer Jean V. Sirles Alice Jean Smith Catherine M. Smith Clarence Smith Mr. and Mrs. Ernest B. Smith Howard G. Smith Kevin L. Smith Patricia Smith Willie Mae Smith Ruth Sneve Vera Marie Snider Esther and Harold Sohmer Fred E. Spencer Jacqueline Spencer William Sprenger Remy R. Sprouse Brenda M. St. James Gerald J. Steinberg Leopold Steindecker Anna Stephan Robert L. Stevens Mary Malcolm Stiles John Strang Fay Strout and Laurence Cecil Strout Frieda Coons Studley Dorothy H. Sullivan Myrtle B. Summers Agnes Katscher Sunley John Supon Mary and James Suthard Mary Carol Talerico Maureen Tannehill Melvin G. Taylor George C. Thomas Jr. Carl E. Thomas Geraldine E. Thomas Overton Arnold Thompson Viola Mae Thompson Anita and John R. Timmel Carola S. Trier Jessie C. Tripp John D. Turkel Zelda M. Uthe Paul E. Van Cleve William R. Vass Josephine S. Villeman Myrtle H. and Antone L. Vinelli Anne D. Vinton Paul H. Volpe Linda Vono Esther and Stanley Wade Ethel Wagner David Walker Robert B. Walker Thomas Walsh Julia Walz Lea Ward Irene M. Watkins Dorothy Waugh Ione A. and Albert L. Weickert Rose C. Weisel Elizabeth A. Weiser Leonard Weiss Robert P. West Anna M. Wheeler Lois V. Wheeler Agnella L. Widmer Geneva K. Widmer Margaret Wiegandt Saul J. Wiener Loretta M. Wiggins Lorna Katherine Wilkinson Francis I. and Harriet B. Wilks Josephine H. Williams Ora Brown Windle Mr. and Mrs. Norman J. Woodhams Frederick W. Woodworth Carolyn and Bill Woody John A. Wootton Josephine Wootton Nettie Wright Ethel R. Young Marion E. Youngberg Gloria Zaino Marion Zell Raelynn and Steve Ziegler Centennial Circle The Centennial Circle celebrates donors who have made a lifelong commitment to supporting the Cancer Research Institute. Members of this loyal group have made 75 or more gifts to CRI during their lifetime. Anonymous (2) Ellen Beloff Mr. and Mrs. Ira M. Boskey Brian M. Brewer Lauren B. Burns Harriet E. Charles Mr. and Mrs. Irving Cohen Aileen Cole Selma Davidson Archibald M. Denny III Mr. and Mrs. Stephen C. Elkin Rhoda Fischman Anne E. Gentile Mr. and Mrs. Gary R. Ginsberg Mr. and Mrs. Leonard Gold Oliver R. Grace Jr. Helen A. Green Renee A. Harris Harvey A. Herbert Mrs. Stephen M. Kellen Col. Richard C. Kowalski Mr. and Mrs. Elliot Leitner Mr. and Mrs. Michael Levy Charles J. Lurie Mr. and Mrs. Charles Lyttle II Thomas G. Mendell Mr. and Mrs. Arthur Nasso Jacques C. Nordeman Bernadette Nuzzo Maxwell D. Osborne Esther Ravin Mr. and Mrs. Jonas J. Rieter Mr. and Mrs. Milton S. Rubin Clifford M. Rutter Joyce Schumer Mr. and Mrs. Sydney Shuman Mr. and Mrs. Brian D. Silverman Mr. and Mrs. Marvin Stillman William Tracy Timothy D. Tucker Mr. and Mrs. Everett L. Wessner Alan N. White Florence Wisler CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 45 FINANCIAL HIGHLIGHTS Your Gift at Work D onor trust is something we value above all else. To earn and maintain this trust, we hold ourselves to the highest standards of accountability and transparency when communicating the financial health of this organization. Seeking to extract maximum impact from every dollar donated, we fund strategically and invest responsibly, keeping an eye to the long view of progress while remaining nimble enough to respond to new opportunities. Our financial records are kept according to best accounting practices, and we open our books annually for inspection and verification by independent auditors. EisnerAmper has conducted an independent audit of the Cancer Research Institute’s financial activities for fiscal year 2016 (July 1, 2015, to June 30, 2016). We provide highlights here, and you can access our complete audited financial statements on our website at cancerresearch.org/financials. PUBLIC SUPPORT & REVENUE (Unrestricted) $ 33.7MM Contributions $26.9MM, 80% includes $9.9MM raised in prior years for FY2016 operations Special Events $2.7MM, 8% Investments & Other $2.2MM, 6% 87 PERCENT OF EXPENSES DEDICATED TO PROGRAMS $336 MILLION INVESTED SINCE 1953 Bequests & Memorials $2.0MM, 6% The continued financial strength of this organization stems not only from the generosity of our donors, but also from the rigorously high standards of accountability to which we hold ourselves. OPERATING EXPENSES $ 31.5MM Research $22.6MM, 72% $23.6MM awarded minus $909K in early terminations from grants made in prior years Education Alfred R. Massidas Chief Financial Officer $4.8MM, 15% Marketing & Fundraising $2.8MM, 9% Administration $1.2MM, 4% CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 47 GOVERNANCE & GUIDANCE Providing Expert Oversight V olunteer scientific and business leaders help the Cancer Research Institute, not only through academic and financial support, but also through astute governance and active participation in the organization’s initiatives. BOARD OF TRUSTEES CHAIRMEN Paul C. Shiverick Co-Founder Seminole Management Company, Inc. New York, NY Andrew K. Tsai Managing Principal Chalkstream Capital Group, L.P. New York, NY VICE CHAIRMEN Edgar R. Berner Partner John Lang, Inc. New York, NY John B. Fitzgibbons Chairman and CEO Basin Holdings US LLC New York, NY TREASURER Geoffrey O. Coley International Business Head Mitsubishi UFJ Securities (USA), Inc. New York, NY SECRETARY Thomas G. Mendell Private Investor T.G. Mendell Corp. New York, NY BOARD Yacov Arnopolin Portfolio Manager, Emerging Markets PIMCO New York, NY Peter L. Bloom Brooklyn, NY Jennifer L. Brorsen Bronxville, NY Donald J. Gogel Chairman and CEO Clayton, Dubilier & Rice, LLC New York, NY James M. Citrin Leader, CEO Practice Spencer Stuart Stamford, CT Jacques C. Nordeman Chairman Nordeman Grimm, Inc. New York, NY Maurice J. Cunniffe Chairman and CEO Vista Capital Corporation Greenwich, CT Andrew M. Paul Managing General Partner Enhanced Equity Funds New York, NY W. Robert Dahl Principal WRD Capital Darien, CT Glenn J. DeSimone Greenwich, CT John E. Eckerson Rye, NY Sean P. Fahey Founding Member and Co-Chief Investment Officer Claren Road Asset Management New York, NY Margot E. Freedman Larchmont, NY Oliver R. Grace Jr. President Associated Asset Management, Inc. Palm Beach, FL Sandra Coudert Graham Oyster Bay, NY Michael M. Kellen Director of First Eagle Holdings, Inc. Vice Chairman of First Eagle Investment Management, LLC New York, NY Alexander P. Lynch Partner White Deer Energy New York, NY Brian Riano Co-Founder and CEO Claren Road Asset Management New York, NY Lief D. Rosenblatt Partner ENE Investco Management New York, NY Frank V. Sica President Tailwind Capital New York, NY James A. Stern Chairman and Founder The Cypress Group, LLC New York, NY Michael B. Targoff Vice Chairman of the Board of Directors Loral Space & Communications New York, NY Diane Tuft New York, NY Heidi J. Ueberroth Director Pebble Beach Company Pebble Beach, CA Lauren S. Veronis New York, NY Ronald G. Weiner President Perelson Weiner LLP New York, NY CRI trustees are fully engaged in our mission because each of us believes in the potential of immunotherapy to conquer all cancers, and each has seen how CRI is able to transform this potential into reality for many cancer patients today. John B. Fitzgibbons Chairman and CEO, Basin Holdings US LLC Vice Chairman, CRI Board of Trustees CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 49 Jim Weiss Founder and CEO W2O Group San Francisco, CA Peter Zhou Senior Managing Director Coatue Management New York, NY Mrs. Charles G. Gambrell Charlotte, NC ASSOCIATE BOARD CHAIRMAN William O. Grabe Advisory Director General Atlantic LLC Greenwich, CT Joyce Green Westhampton Beach, NY Tyler Hassen President Basin Power New York, NY Howard P. Berkowitz HPB Associates New York, NY Donald G. Calder Chairman Clear Harbor Asset Management New York, NY Stuart P. Davidson Managing Director Labrador Ventures San Francisco, CA Bruce D. Dixon Retired Partner Ernst & Young Greenwich, CT Ann W. Jackson New York, NY Arthur L. Jacobson Vice President, Investments Smith Barney Indian Wells, CA Robert A. Posner Managing Director Commonwealth Holding, LP Brookline, MA Julian H. Robertson Jr. Chairman Tiger Management, LLC New York, NY Winthrop H. Smith Jr. Chairman Summit Ventures NE, LLC Warren, VT SCIENTIFIC ADVISORY COUNCIL Niko Gubernator, Ph.D. Chief Executive Officer eMolecules La Jolla, CA James P. Allison, Ph.D. The University of Texas MD Anderson Cancer Center Houston, TX Nick Hammerschlag Founder and Managing Partner Martellus Holdings New York, NY ASSOCIATE DIRECTORS Adler Bernard Counsel JPMorgan Chase & Co. New York, NY Jennifer Box, CFA Managing Director Oaktree Capital Management, L.P. New York, NY Rada Cevher Business Development Wealth-X New York, NY Eash Cumarasamy Chief Financial Officer Basin Industries New York, NY Edward Donkor Principal, Energy Investment Team Pine Brook Partners New York, NY Michael Fisher Vice President Enhanced Equity Funds New York, NY Samantha Knapik Consultant Fortress Investment Group New York, NY Trent Kososki Principal Energy Capital Partners Short Hills, NJ Maggie Moore Vice President, Urban Investment Group Goldman Sachs New York, NY Ashton Valente General Counsel Basin Holdings New York, NY Harvey Cantor, M.D. Dana-Farber Cancer Institute Boston, MA DIRECTOR MEMBERS TRUSTEES EMERITI Carter F. Bales Chairman and Managing Director NewWorld Capital Group, LLC New York, NY Andrew Goldman Managing Director Anchorage Capital Group New York, NY Glenn Dranoff, M.D. Novartis Institutes for BioMedical Research Cambridge, MA Carl F. Nathan, M.D. Weill Cornell Medicine New York, NY Jonathan S. Cebon, Ph.D., FRACP Austin Health/Ludwig Cancer Research Melbourne, Australia Vincenzo Cerundolo, M.D., Ph.D. MRC Human Immunology Unit, University of Oxford Oxford, United Kingdom Max D. Cooper, M.D. Emory University School of Medicine Atlanta, GA Ellen Puré, Ph.D. University of Pennsylvania Philadelphia, PA Lisa M. Coussens, Ph.D. Knight Cancer Institute Oregon Health & Science University Portland, OR Robert D. Schreiber, Ph.D. Washington University School of Medicine St. Louis, MO Peter Cresswell, Ph.D. Yale University School of Medicine New Haven, CT Jedd D. Wolchok, M.D., Ph.D. Memorial Sloan Kettering Cancer Center and Ludwig Cancer Research New York, NY Charles G. Drake, M.D., Ph.D. NewYork-Presbyterian/ Columbia University Medical Center New York, NY MEMBERS Michael L. Dustin, Ph.D. University of Oxford Oxford, United Kingdom Frederick W. Alt, Ph.D. Boston Children’s Hospital and Harvard Medical School Boston, MA Richard Axel, M.D. Columbia University Medical Center New York, NY Nina Bhardwaj, M.D., Ph.D. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York, NY Richard A. Flavell, Ph.D., FRS Yale University School of Medicine New Haven, CT Thomas F. Gajewski, M.D., Ph.D. The University of Chicago Chicago, IL Laurie H. Glimcher, M.D. Dana-Farber Cancer Institute Boston, MA CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 51 Philip D. Greenberg, M.D. University of Washington School of Medicine and Fred Hutchinson Cancer Research Center Seattle, WA Axel Hoos, M.D., Ph.D. GlaxoSmithKline Collegeville, PA Patrick Hwu, M.D. The University of Texas MD Anderson Cancer Center Houston, TX Elizabeth M. Jaffee, M.D. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine Baltimore, MD Carl H. June, M.D. Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA Michael Kalos, Ph.D. Eli Lilly & Company New York, NY Michael Karin, Ph.D. University of California, San Diego La Jolla, CA John M. Kirkwood, M.D. University of Pittsburgh Cancer Institute Pittsburgh, PA George Klein, M.D., D.Sc. Karolinska Institute Stockholm, Sweden Alexander Knuth, M.D. National Center for Cancer Care and Research, Hamad Medical Corporation Doha, Qatar Lewis L. Lanier, Ph.D. University of California, San Francisco San Francisco, CA Hyam I. Levitsky, M.D. Juno Therapeutics Seattle, WA Dan R. Littman, M.D., Ph.D. NYU Langone Medical Center New York, NY Nils Lonberg, Ph.D. Bristol-Myers Squibb Milpitas, CA Tak W. Mak, Ph.D., D.Sc., FRSC The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, University Health Network, University of Toronto Toronto, Canada Klaus Rajewsky, M.D. Max-Delbrück Center for Molecular Medicine Berlin, Germany Mark J. Smyth, Ph.D. QIMR Berghofer Medical Research Institute Queensland, Australia CVC TRIALS NETWORK Anjana Rao, Ph.D. La Jolla Institute for Allergy and Immunology, Sanford Consortium for Regenerative Medicine La Jolla, CA Pramod K. Srivastava, M.D., Ph.D. University of Connecticut Health Center Farmington, CT Jedd D. Wolchok, M.D., Ph.D. Memorial Sloan Kettering Cancer Center and Ludwig Cancer Research New York, NY Jeffrey V. Ravetch, M.D., Ph.D. The Rockefeller University New York, NY Stanley R. Riddell, M.D. Fred Hutchinson Cancer Research Center Seattle, WA Philippa C. Marrack, Ph.D. National Jewish Health and the University of Colorado Denver Denver, CO Alexander Y. Rudensky, Ph.D. Memorial Sloan Kettering Cancer Center New York, NY Cornelis J.M. Melief, M.D., Ph.D. Leiden University Medical Center Leiden, The Netherlands Bijan Safai, M.D., D.Sc. New York Medical College Valhalla, NY Ira Mellman, Ph.D. Genentech South San Francisco, CA Shimon Sakaguchi, M.D., Ph.D. Immunology Frontier Research Center, Osaka University Osaka, Japan Malcolm A.S. Moore, D.Phil. Memorial Sloan Kettering Cancer Center New York, NY Lawrence E. Samelson, M.D. National Cancer Institute, NIH Bethesda, MD Lee Nadler, M.D. Dana-Farber Cancer Institute Boston, MA Hans Schreiber, M.D., D.MSc., Ph.D. The University of Chicago Chicago, IL Kunle Odunsi, M.D., Ph.D. Roswell Park Cancer Institute Buffalo, NY Ton N. Schumacher, Ph.D. The Netherlands Cancer Institute and Kite Pharma Amsterdam, The Netherlands Drew M. Pardoll, M.D., Ph.D. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine Baltimore, MD Craig L. Slingluff Jr., M.D. University of Virginia School of Medicine Charlottesville, VA Susumu Tonegawa, Ph.D. Massachusetts Institute of Technology Cambridge, MA Giorgio Trinchieri, M.D. National Cancer Institute, NIH Frederick, MD DIRECTOR AND SCIENTIFIC ADVISORY COMMITTEE CHAIR SCIENTIFIC ADVISORY COMMITTEE Jonathan S. Cebon, Ph.D., FRACP Austin Health/Ludwig Cancer Research Melbourne, Australia Ulrich H. von Andrian, M.D., Ph.D. Harvard Medical School and Boston Children’s Hospital, Boston; The Ragon Institute of Massachusetts General Hospital, MIT, and Harvard University Cambridge, MA George Coukos, M.D., Ph.D. University Hospital of Lausanne (CHUV) Lausanne, Switzerland Hao Wu, Ph.D. Boston Children’s Hospital and Harvard Medical School Boston, MA Cassian Yee, M.D. The University of Texas MD Anderson Cancer Center Houston, TX Rolf M. Zinkernagel, M.D., Ph.D. University of Zürich Zürich, Switzerland Antoni Ribas, M.D., Ph.D. UCLA Medical Center Los Angeles, CA Michel Sadelain, M.D., Ph.D. Memorial Sloan Kettering Cancer Center New York, NY Neil H. Segal, M.D., Ph.D. Memorial Sloan Kettering Cancer Center New York, NY Nina Bhardwaj, M.D., Ph.D. Icahn School of Medicine at Mount Sinai New York, NY Emil R. Unanue, M.D. Washington University School of Medicine St. Louis, MO Robert H. Vonderheide, M.D., D.Phil. Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA Kunle Odunsi, M.D., Ph.D. The Roswell Park Cancer Institute Buffalo, NY Lawrence Fong, M.D. University of California, San Francisco San Francisco, CA Dirk Jäger, M.D. National Center for Tumor Diseases, University of Heidelberg Heidelberg, Germany Elizabeth M. Jaffee, M.D. Johns Hopkins University School of Medicine Baltimore, MD Carl H. June, M.D. Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA Andrew G. Sikora, M.D. Baylor College of Medicine Houston, TX Craig L. Slingluff Jr., M.D. University of Virginia Cancer Center Charlottesville, VA Pramod K. Srivastava, M.D., Ph.D. University of Connecticut Health Farmington, CT Marcel R.M. van den Brink, M.D., Ph.D. Memorial Sloan Kettering Cancer Center New York, NY Robert H. Vonderheide, M.D., D.Phil. Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA E. John Wherry, Ph.D. Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA Matthew F. Krummel, Ph.D. University of California, San Francisco San Francisco, CA CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 53 FINANCE, INTELLECTUAL PROPERTY, CLINICAL TRIALS MANAGEMENT, AND ADMINISTRATION CANCER RESEARCH INSTITUTE Adam Kolom Vanessa M. Lucey, Ph.D., MBA Jill O’Donnell-Tormey, Ph.D. LUDWIG CANCER RESEARCH Pär Olsson, Ph.D. Aileen Ryan Jonathan Skipper, Ph.D. Ralph Venhaus, M.D. GLOBAL CLINICIAN AND SCIENTIST MEMBERSHIP UNITED STATES • James P. Allison, Ph.D., The University of Texas MD Anderson Cancer Center • Shahab Asgharzadeh, M.D., University of Southern California • Djordje Atanackovic, M.D., University of Utah • Mark Awad, M.D., Ph.D., DanaFarber Cancer Institute • Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai • Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center • Timothy A. Chan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center • Aude G. Chapuis, M.D., Fred Hutchinson Cancer Research Center • Hearn Jay Cho, M.D., Ph.D., Icahn School of Medicine at Mount Sinai • Adam D. Cohen, M.D., University of Pennsylvania • Patrick Dillon, M.D., University of Virginia Health System • Gavin P. Dunn, M.D., Ph.D., Washington University School of Medicine • Lawrence Fong, M.D., University of California, San Francisco • Leena Gandhi, M.D., Ph.D., NYU Langone Medical Center • Sacha Gnjatic, Ph.D., Icahn School of Medicine at Mount Sinai • Philip D. Greenberg, M.D., Fred Hutchinson Cancer Research Center, University of Washington • F. Stephen Hodi Jr., M.D., DanaFarber Cancer Institute, Harvard Medical School • Siwen Hu-Lieskovan, M.D., Ph.D., UCLA Medical Center • Elizabeth M. Jaffee, M.D., Johns Hopkins University School of Medicine • Carl H. June, M.D., University of Pennsylvania • Achim Jungbluth, M.D., Memorial Sloan Kettering Cancer Center • Thomas J. Kaley, M.D., Memorial Sloan Kettering Cancer Center • John M. Kirkwood, M.D., University of Pittsburgh Medical Center • Matthew F. Krummel, Ph.D., University of California, San Francisco • Alexander M. Lesokhin, M.D., Memorial Sloan Kettering Cancer Center • Kunle Odunsi, M.D., Ph.D., Roswell Park Cancer Institute • Hideho Okada, M.D., Ph.D., University of California, San Francisco • Drew M. Pardoll, M.D., Ph.D., Johns Hopkins University School of Medicine • Marshall R. Posner, M.D., Icahn School of Medicine at Mount Sinai • Osama E. Rahma, M.D., University of Virginia Health System • David A. Reardon, M.D., DanaFarber Cancer Institute • Antoni Ribas, M.D., Ph.D., UCLA Medical Center • Michel Sadelain, M.D., Ph.D., Memorial Sloan Kettering Cancer Center • Yvonne Saenger, M.D., Columbia University Medical Center • Jonathan D. Schoenfeld, M.D., M.Phil., MPH, Dana-Farber Cancer Institute • Neil H. Segal, M.D., Ph.D., Memorial Sloan Kettering Cancer Center • Padmanee Sharma, M.D., Ph.D., The University of Texas MD Anderson Cancer Center • Andrew G. Sikora, M.D., Ph.D., Baylor College of Medicine • Craig L. Slingluff Jr., M.D., University of Virginia Health System • Alexandra Snyder Charen, M.D., Memorial Sloan Kettering Cancer Center • Pramod K. Srivastava, M.D., Ph.D., University of Connecticut School of Medicine • Mario Sznol, M.D., Yale Cancer Center • Suzanne L. Topalian, M.D., Johns Hopkins University School of Medicine • Cornelia L. Trimble, M.D., Johns Hopkins University School of Medicine • Takemasa Tsuji, Ph.D., Roswell Park Cancer Institute • Marcel R.M. van den Brink, M.D., Ph.D., Memorial Sloan Kettering Cancer Center • Robert H. Vonderheide, M.D., D.Phil., University of Pennsylvania • Ralph R. Weichselbaum, M.D., University of Chicago • E. John Wherry, Ph.D., University of Pennsylvania • Jedd D. Wolchok, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research • Cassian Yee, M.D., The University of Texas MD Anderson Cancer Center • Dmitriy Zamarin, M.D., Ph.D., Memorial Sloan Kettering Cancer Center • Hassane M. Zarour, M.D., University of Pittsburgh Medical Center • Lei Zheng, M.D., Ph.D., Johns Hopkins University School of Medicine EUROPE • Maha Ayyoub, Ph.D., Institut Gustav Roussy, Villejuif, France • Luigi Buonaguro, M.D., National Cancer Institute Pascale, Italy • Vincenzo Cerundolo, M.D., Ph.D., University of Oxford, United Kingdom • George Coukos, M.D., Ph.D., University Hospital of Lausanne, Switzerland • Jessica Cecile Hassel, M.D., University Clinic of Heidelberg, Germany • Dirk Jäger, M.D., University Clinic of Heidelberg, Germany • Elke Jäger, M.D., Krankenhaus Nordwest, Germany • Lana E. Kandalaft, Pharm.D., Ph.D., University Hospital of Lausanne, Switzerland • Judith Kroep, M.D., Ph.D., Leiden University Medical Center, The Netherlands • Simon A. Laban, M.D., University of Ulm, Germany • James Larkin, FRCP, Ph.D., The Royal Marsden NHS Foundation Trust, United Kingdom • Xin Lu, Ph.D., University of Oxford, Ludwig Cancer Research, United Kingdom • Cornelis J.M. Melief, M.D., Ph.D., Leiden University Medical Center, The Netherlands • Mark R. Middleton, M.D., Ph.D., University of Oxford, United Kingdom • Dario Neri, Ph.D., Swiss Federal Institute of Technology Zürich, Switzerland • Christian Ottensmeier, M.D., Ph.D., FRCP, University of Southampton, United Kingdom • Pedro J. Romero, M.D., University Hospital of Lausanne, Switzerland • Daniel E. Speiser, M.D., University Hospital of Lausanne, Switzerland • Danila Valmori, Ph.D., Centre de Lutte Contre Le Cancer NantesAtlantique, France • Nicolas Van Baren, M.D., Ph.D., Université Catholique de Louvain, Ludwig Cancer Research, Belgium • Maries van den Broek, Ph.D., University of Zürich, Switzerland • Benoit J. Van den Eynde, M.D., Ph.D., Université Catholique de Louvain, Ludwig Cancer Research, Belgium • Pierre van der Bruggen, Ph.D., Université Catholique de Louvain, Ludwig Cancer Research, Belgium • Sjoerd Henricus van der Burg, Ph.D., Leiden University Medical Center, The Netherlands • Magnus von Knebel Doeberitz, M.D., University Clinic of Heidelberg, Germany • Alfred Zippelius, M.D., University of Basel, Switzerland ASIA • Shinichi Kageyama, M.D., Mie University School of Medicine, Japan • Alexander Knuth, M.D., National Center for Cancer Care and Research, Hamad Medical Corporation, Qatar • Eiichi Nakayama, M.D., Ph.D., Kawasaki University of Medical Welfare, Japan • Hiroyoshi Nishikawa, M.D., Ph.D., National Cancer Center Hospital, Japan • Hiroshi Shiku, M.D., Mie University School of Medicine, Japan • Hisashi Wada, M.D., Ph.D., Osaka University, Japan The Clinical Accelerator has a network of nearly 90 leading cancer immunologists across 12 countries, who bring unparalleled expertise to the design, planning, and execution of our clinical trials. Adam Kolom Clinical Accelerator Australia • Jonathan S. Cebon, Ph.D., FRACP, Austin Health, Ludwig Cancer Research • Mark J. Smyth, Ph.D., FAHMS, QIMR Berghofer Medical Research Institute CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 55 CANCER IMMUNOTHERAPY CONSORTIUM Michael Kalos, Ph.D. Eli Lilly & Company New York, NY STEERING COMMITTEE CHAIRS Daniel S. Chen, M.D., Ph.D. Genentech South San Francisco, CA Axel Hoos, M.D., Ph.D. GlaxoSmithKline Collegeville, PA MEMBERS Cedrik M. Britten, M.D. GlaxoSmithKline Stevenage, United Kingdom Roger D. Dansey, M.D. Merck Research Laboratories Rahway, NJ Glenn Dranoff, M.D. Novartis Institutes for BioMedical Research Cambridge, MA Robert M. Hershberg, M.D., Ph.D. Celgene and VentiRx Pharmaceuticals Seattle, WA YOUNG PHILANTHROPISTS COUNCIL STAFF SENIOR STAFF Shasell Negron General Manager / Workplace Giving Campaign Manager BOARD Nils Lonberg, Ph.D. Bristol-Myers Squibb Milpitas, CA Israel Lowy, M.D., Ph.D. Regeneron Tarrytown, NY Ira Mellman, Ph.D. Genentech, Inc. South San Francisco, CA David M. Reese, M.D. Amgen Thousand Oaks, CA Arvin Yang, M.D., Ph.D. Bristol-Myers Squibb Princeton, NJ Priyanka Sewhani All About the Optics New York, NY Catherine Borod Partners & Spade New York, NY Anna-Nora Bernstein Freelance Film Producer New York, NY Ali Urman Montefiore Medical Center New York, NY Anna Maria Barbuti St. Johns University New York, NY Jill O’Donnell-Tormey, Ph.D. Chief Executive Officer and Director of Scientific Affairs Brian M. Brewer Director of Marketing and Communications Lynne A. Harmer Director of Grants Administration and Special Events Alfred R. Massidas Chief Financial Officer and Director of Human Resources Sharon Slade Director of Strategic Initiatives Alexa Schles Graphic Designer Devi Sharma Donations Processing Manager Marla A. Sincavage Associate Director, Corporate and Foundation Relations Denise Upton Manager of Grants Administration Jasmine Wright Events Coordinator and Assistant to the CEO Qing Hua Zhang Controller STAFF CONSULTANT Samuel Obletz Goldman Sachs New York, NY Marissa Kaplan Verathon Inc. New York, NY Megan Bannigan Debevoise & Plimpton LLP New York, NY Brittany Lett Cognito New York, NY MEMBERS Natalie Berner Linda Foit Sean Kiely Jaskaren Randhawa Diana Rosario Arthur N. Brodsky, Ph.D. Science Writer Rupinder Kaur Senior Manager of Operations and Officer of Planned Giving Adam Kolom Managing Director, Clinical Accelerator Michelle Liew Digital Media Manager Melinda Lopez Receptionist/ Administrative Assistant Vanessa M. Lucey, Ph.D., MBA Associate Director, Clinical Venture Fund and Accelerator Caitlin Mackaman Manager of Individual Giving Katherine McCluskey Event Coordinator CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 57 WAYS TO GIVE Lasting Impact T he Cancer Research Institute has a long tradition of responsible stewardship of donor funds. We receive the highest marks from charity watchdog groups, including four out of four stars from Charity Navigator and an “A” grade from CharityWatch. CRI also meets all 20 standards of the Better Business Bureau Wise Giving Alliance. Donors to CRI can be confident that their donation, in any amount, will do the most good possible. OUTRIGHT GIFTS Cash Donations by check or credit card may be sent directly to the Cancer Research Institute or processed through our secure website at cancerresearch.org/donate Property Other Than Cash Donating securities, automobiles, and similar properties can often be a tax-efficient method for making a meaningful gift to CRI. Visit cancerresearch.org/ways-to-give Workplace Giving Programs Ask your human resources department if your company may have a plan through which you can contribute to CRI, or contact us to learn how to set up a program at your workplace. Matching Gifts You can contact your human resources department to inquire if your employer matches contributions, or browse our online matching gift database to see if your company is listed at cancerresearch.org/match Planned Gifts Include bequests made through a living trust or inclusion of the Cancer Research Institute in your will as a beneficiary of cash, securities, or personal property. Your bequest should include the Institute’s federal tax ID number (13-1837442) and a statement such as the following: “I bequeath to the Cancer Research Institute, a not-for-profit corporation of the State of New York, having its principal office at One Exchange Plaza, 55 Broadway, Suite 1802, New York, New York 10006, the sum of $ for its general operating purposes.” ALEXANDER M. LESOKHIN, M.D., A CRI-FUNDED CLINICAL INVESTIGATOR AT MEMORIAL SLOAN KETTERING CANCER CENTER IN NEW YORK, NY, IS TESTING TWO PROMISING CHECKPOINT IMMUNOTHERAPIES, DURVALUMAB AND TREMELIMUMAB, IN A CLINICAL TRIAL FOR PATIENTS WITH MULTIPLE MYELOMA. Community Fundraising Want to hold a bake sale to raise money for cancer research? How about a fashion show, dinner, or a music concert? Maybe you’re getting married and would prefer guests give to charity in lieu of gifts. We offer support for these and other fundraising ideas. Visit cancerresearch.org/fundraise to learn more about how you can organize your own special event and become a part of Team CRI. FOR CORPORATE PARTNERS No one organization, company, or group can solve the cancer problem alone. It takes collaboration to change the course of cancer. CRI actively seeks out and welcomes opportunities to work together with others to develop educational and awareness-building programs designed to advance the pace of progress in cancer immunotherapy research. Contact Sharon Slade at [email protected] or (212) 688-7515 x230 to learn more. To help you make the most fitting and fulfilling contribution to CRI, please contact our Development Office at (212) 688-7515 or send an email to [email protected]. You should, of course, always consult your attorney and tax advisor for the formal writing of your will and to discuss the tax implications of any form of planned giving. Learn more online at legacy.cancerresearch.org. CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 59 NATIONAL HEADQUARTERS One Exchange Plaza 55 Broadway, Suite 1802 New York, NY 10006 Tel. (212) 688-7515 Toll-Free (800) 99-CANCER Fax (212) 832-9376 Email [email protected] VOLUNTEER OFFICES 344 Hauser Boulevard, Unit 422 Los Angeles, CA 90036 Tel. (323) 935-2520 101 University Avenue, 4th Floor Palo Alto, CA 94301 Tel. (650) 365-6441 80 Field Point Road Greenwich, CT 06830 Tel. (203) 622-0522 184 Fisher Avenue Brookline, MA 02445 Tel. (617) 566-0100 2802 Flintrock Trace, Suite 220 Austin, TX 78738 Tel. (512) 610-5530 122 River Run Road Lancaster, VA 22503 Tel. (703) 759-0835 CANCERRESEARCH.ORG